skip to main |
skip to sidebar
CROI 2010 - Full Sessions Abstracts
Sessions 1-204/204
- Program
Committee Workshop for New Investigators and Trainees
- HIV
Virology
and Pathogenesis: Emerging Concepts
- HIV
Immunology
and Vaccines
- HIV
Transmission:
The Role of Neutralizing Antibodies
- Global
Epidemiology
- HIV
Prevention
- ART
is
great
- Complications
of
HIV Disease and ART
- Community
Involvement
in AIDS Research: Past, Present, and Future
- Frontiers
in Laboratory Science Workshop
- Sensitive
Population
Profiling and Genome Assembly of HIV Using Ultra-deep
Sequencing Technologies
- Whole
Genome
Sequencing and the Control of HIV-1
- Can
Systems
and Computational Virology Help Us Understand AIDS Pathogenesis
and Develop Better Drugs and Vaccines?
- Pitfalls
in
Analysis of Large-scale Data
- Guiding
the Global Response
- Put
Your
Money Where Your Model Is: ART for the Prevention and Treatment of
HIV/AIDS
- HIV
in
Couples
- Evolving
Realities
of HIV Treatment in Resource-limited Settings
- The
Future of PEPFAR
- The
Future
of PEPFAR: Moving Forward from Lessons Learned
- The
HIV/AIDS Research Agenda: A View from NIAID
- The
HIV/AIDS
Research Agenda: A View from NIAID
- 15th
Bernard Fields Lecture and 4th N'Galy-Mann Lecture
- Transmitted/Founder
Viruses
and Their Progeny in Acute HIV-1 and SIV Infection
- Saints
and
Sinners: A Story of HIV from India
- Putting
the “C” into MTCT—Saving Kids
- Putting
the
“C” into MTCT—Saving Kids
- HIV-1
Assembly, Release, and Maturation
- HIV-1
Assembly,
Release, and Maturation
- Developments
in the Epidemiology of SIV/HIV in AIDS-related
Malignancies
- Molecular
Epidemiology
of SIV Infection in Wild-living Gorillas in Western
Equatorial Africa
- HIV-1
Group
P: Confirmation of Group P in Cameroon
- The
Role
of Recombination in the Emergence of a Complex and Dynamic HIV
Epidemic
- Cancer
Incidence
and Cancer-attributable Mortality among Persons with AIDS in
the US
- Immunodeficiency,
HIV
RNA Levels, and Risk of Non-AIDS-defining Cancers
- Effectiveness
of
a Program to Prevent Cervical Cancer among HIV-infected Women in
Zambia
- HIV
Infection
Is an Independent Risk Factor for Lung Cancer
- A
Phase
II Study Targeting Vascular Endothelial Growth Factor with the
Humanized Monoclonal Antibody Bevacizumab in the Treatment of Patients
with HIV-associated Kaposi Sarcoma
- The
KAART
Trial: A Randomized Controlled Trial of HAART Compared to the
Combination of HAART and Chemotherapy in Treatment Naive Patients with
HIV-associated Kaposi’s Sarcoma in KwaZulu-Natal, South Africa NCT
00380770
- Testing
and Transmission
- Decreases
in
Community Viral Load Are Associated with a Reduction in New HIV
Diagnoses in San Francisco
- Monitoring
the
Impact of Expanded HIV Testing in the District of Columbia Using
Population-based HIV/AIDS Surveillance Data
- Increasing
Trend
in HIV-1 Incidence among Young Men Who Have Sex with Men in
Amsterdam: A 25-year Prospective Cohort Study
- Population-based
HIV
Incidence in France, 2003 to 2008
- Trends
in
HIV Prevalence, Incidence, and Risk Behaviors Among Children, Youth,
and Adults in South Africa, 2002 to 2008
- HIV
Transmission
Risk among HIV-infected Adults in Kenya: Results of a
Population-based Survey
- Female
Clients
and Partners of MSM Sex Workers in Mombasa, Kenya
- Factors
Associated
with HIV Discordance in Married or Cohabitating Couples:
Results from a Nationally Representative Survey in Kenya
- What’s
New in Immunopathogenesis
- Dramatic
Changes
in Fc-Receptor Expression during HIV-1 Infection Associated
with Reduced Phagocytic Activity during Progressive HIV-1 Infection
- Evolution
of
Neutralizing Antibody Responses and Viral Escape Continues until
Advanced Infection and Is Associated with Broad Neutralizing Antibody
Activity
- Adaptation
of
HIV-1 Envelope Glycoprotein to Humoral Immunity at a Population
Level
- Damage
to
Mucosal Integrity Correlates with Increased Microbial Translocation
and Loss of NK Cells, and Is Associated with Rapid SIV Disease
Progression in Pigtail Macaques
- Interleukin-21
Immune-mediated
Control of HIV-1 by HIV-1-specific CD8 T Cells
- Antiviral
Suppressive
Capacity of CD8+ T Cells ex vivo Is Strongly Associated
with the Rate of CD4 Cell Loss in Chronic HIV-1 Infection
- Immune
Failure
after Suppressive ART: High Level CD4 and CD8 T Cell Activation
but Only Memory CD4 Cells Are Cycling
- Systems
Biology
Approaches to the Understanding of HIV Immunopathogenesis
- Advances
in
ART
- First-in-class
Inhibitors
of LEDGF/p75-integrase Interaction and HIV replication
- Discovery
of
Potent HIV-1 Capsid Assembly Inhibitors
- Instantaneous
Inhibitory
Potential Is Similar to Inhibitory Quotient at Predicting
HIV-1 Response to ART
- Multiple
Equilibrium
Model Predicts Class-specific Steep Dose-response Curve
Slope for Anti-HIV-1 Drugs
- Safety
and
Efficacy of TBR 652, a CCR5 Antagonist, in HIV-1-infected,
ART-experienced, CCR5 Antagonist-naïve Patients
- Phase
3
Trials of Vicriviroc in Treatment-experienced Subjects Demonstrate
Safety but Not Significantly Superior Efficacy over Potent Background
Regimens Alone
- The
Discovery
of S/GSK1349572: A Once-daily Next Generation Integrase
Inhibitor with a Superior Resistance Profile
- Risk
of
WHO 4 Events and Death by Current CD4 on ART in the DART Trial: The
Impact of CD4-dependent Reporting Bias
- Efficacy
and
Safety at 48 Weeks of Once-daily vs Twice-daily DRV/r in
Treatment-experienced HIV-1+ Patients with No DRV Resistance-associated
Mutations: The ODIN Trial
- Single-tablet,
Fixed-dose
Regimen of Elvitegravir/Emtricitabine/Tenofovir Disoproxil
Fumarate/GS-9350 Achieves a High Rate of Virologic Suppression and
GS-9350 Is an Effective Booster
- ACTG
5202:
Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in
Treatment-naive HIV-infected Patients
- TD:
NeuroAIDS
Treatment Issues and Controversies
- Higher
CD4
Nadir Is Associated with Reduced Rates of HIV-associated
Neurocognitive Disorders in the CHARTER Study: Potential Implications
for Early Treatment Initiation
- Correlates
of
Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER
Cohort
- No
Decrease
in Intrathecal Immunoactivation during Treatment
Intensification in Patients on Stable ART
- CSF
Escape
Is Uncommon in HIV-1-infected Patients on Stable ART
- Neuropsychological
Performance
Is Better in HIV-infected Subjects Treated with Neuroactive
HAART
- cART
Alters
Changes in Cerebral Function Testing after 48 Weeks in
Treatment-naïve, HIV-1-infected Subjects Commencing cART
- CNS
Toxicity
of Antiretroviral Drugs
- TD:
What
Monkey Models Can Teach Us about HIV Infection
- CCR5
Blockade
Alters the in vivo Trafficking of CCR5+ and CD25+ T Cells in
Healthy, SIV-uninfected Rhesus Macaques
- SIVmac239-mediated
Down-modulation
of Integrin alpha4beta7 on Infected Cells
- Systems
Biology
Analysis of CD8 Lymphocyte Depletion in SIV-infected Rhesus
Macaques
- Chronic
SIV
Infection Perturbs the Functional and Phenotypic Heterogeneity of
Macaque NK Cell Subsets
- Natural
Killer
T Cells in Sooty Mangabeys Are Phenotypically Distinct from
Asian Macaques and Are Maintained following SIV Infection
- Nonpathogenic
SIV
Infection of Sooty Mangabeys Induces an LPS-specific Reduction in
Monocyte Inflammatory Cytokine Production
- TD:
Prediction
of HIV Co-receptor Use
- Predicting
HIV-1
Co-receptor Usage and Response to CCR5 Inhibitor Therapy through
Episomal cDNA
- Determining
HIV-1
Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic
Blood Samples
- New
V3-genetic
Signatures Modulate Co-receptor Usage in vivo and the
Interaction with CCR5 N-terminus
- A
Highly
Sensitive and Specific Model for Predicting HIV-1 Tropism in
Treatment-Experienced Patients Combining V3 Loop Sequences
Interpretation and Clinical Parameters
- High
Resolution
Tropism Kinetics by Quantitative Deep Sequencing in
HIV-1-infected Subjects Initiating Suppressive First-line ART
- Large-scale
Application
of Deep Sequencing Using 454 Technology to HIV Tropism
Screening
- TD:
Hepatitis
B and C: The Next Chapter in the Management of HIV in
Resource-limited Countries
- High
Prevalence
of Unexplained Liver Fibrosis Associated with HIV in Rural
Southwestern Uganda
- Response
to
Antiretroviral Therapy (ART) in Hepatitis B and HIV Co-infected West
Africans
- Factors
Associated
with Hepatotoxicity in an International HIV/HBV Co-infected
Cohort on Long-term HAART
- Characterization
of
Hepatitis B Virus (HBV) and its Association with HIV in an
Antiretroviral Therapy(ART)-naïve, Multi-national Cohort from 2
Randomized Controlled Trials (RCT) of the AIDS Clinical Trials Group
(ACTG)
- Prevalence
of
Hepatitis C Virus Infection among Human Immunodeficiency Virus
Type-1 Infected Pregnant Women in Malawi: The BAN Study
- Prevalence
of
Hepatitis B and C Co-infection and Response to Antiretroviral
Therapy among HIV-infected Patients in an Urban Setting in Tanzania
- Prevalence
and
Clinical Course of Occult Hepatitis B (HBV) Infection in Serology
Negative HIV Patients in Johannesburg, South Africa (SA)
- HBV
Polymerase
and Surface Mutations in a Cohort of HIV/HBV Co-infected
Patients Accessing Lamivudine-based HAART in Kumasi, Ghana
- TD:
Got
Milk? Vitamin D Deficiency Prevalence and Associations
- Assessment
of
Vitamin D Levels among HIV-infected Persons in the Study to
Understand the Natural History of HIV/AIDS in the Era of Effective
Therapy (SUN Study)
- Prevalence
of
Hypovitaminosis D among HIV+ Patients Enrolled in a Large Italian
Cohort
- High
Prevalence
of Severe Vitamin D Deficiency in cART Naïve and
Successfully Treated Swiss HIV Patients
- Vitamin
D
and HIV-related Complications and HIV Disease Progression in Women in
Tanzania
- Vitamin
D
Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected
Women in the United States
- New
Strategies
for a Changing Epidemic
- Barriers
to
Barriers
- HIV
Prevention
and Care through Door-to-Door HIV Testing and Counseling:
Opportunities and Challenges
- Male
Circumcision
Scale-up
- Antiretrovirals
for
HIV Prevention: Panacea or Pandora’s Box?
- Targeting
the
HIV-1 Envelope Glycoprotein
- Targeting
the
Membrane Proximal External Region of HIV-1 gp41
- Binding
Requirements
for the Entry Inhibitor BMS-806
- Engineering
Immunity
against HIV-1
- Conserved
Neutralizing
Targets on the HIV-1 Envelope Spike
- Pathogenesis
and
Clinical Management of Complications
- Pathogenesis
and
Management of Visceral Fat Accumulation
- Hepatic
Steatosis,
Pathogenesis, and Management
- HIV,
Inflammation,
and Cardiovascular Disease
- Growing
up
with HIV: Consequences of a Lifetime of ART
- The
US
Epidemic—Disparities in HIV Disease, Care, and Outcomes
- The
US
Epidemic—Disparities in HIV Disease, Care, and Outcomes
- Pathogenic
vs
Nonpathogenic Retrovirus Infections
- Pathogenic
vs
Nonpathogenic Retrovirus Infections
- HIV
Vaccines:
The Path Forward
- RV
144
Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1
Infection in Thai Adults
- Vaccine-induced
Changes
in Breakthrough HIV-1 Sequences from the Step Trial
- Factors
Associated
with Viral Rebound in HIV-Positive Subjects Receiving a
Therapeutic HIV-1 gag Vaccine
- A
Phase
I Double-blind Placebo-controlled Randomized Study of a
Therapeutic Vaccine Using Autologous DC Loaded with Autologous HIV-1 in
Untreated Patients with Asymptomatic Chronic HIV Infection
- Optimal
Priming
of Poxvirus Vector-based HIV Vaccine Regimens Requires 3 DNA
Injections: Results of the Randomized Multicentre EV03/ANRS Vac20 Phase
I/II Trial
- Preclinical
Studies
on DNA/MVA Vaccines: Co-expressed GM-CSF, a Strong Adjuvant for
Prevention of Infection
- Expansion
in
vivo of Naïve and Activated Treg in IL-2-treated HIV Patients
- Lentiviral
Vector-based
Anti-HIV-1 Vaccine Induces Strong T Cell and Antibody
Responses in Macaques, with and without DNA Priming
- Broad
HIV
Neutralizing Antibodies Can Be Elicited by the GBV-C glycoprotein
E2 and Neutralize HIV via a 2F5-like Mechanism
- Antiretroviral-based
Prevention:
Exposure and Efficacy
- Efficacy
of
Intermittent Prophylaxis with Tenofovir and Emtricitabine against
Rectal SHIV Transmission in Macaques and Relationship to Systemic and
Mucosal Drug Levels
- Protection
of
Rhesus Macaques from Vaginal Infection by Maraviroc, an Inhibitor of
HIV-1 Entry via the CCR5 Co-receptor
- Antiretrovirals
for
Prevention: Maraviroc Exposure in the Semen and Rectal Tissue of
Healthy Male Volunteers after Single and Multiple Dosing
- Validating
Measures
of Tenofovir Drug Exposure in a US Pre-exposure Prophylaxis
Trial
- PRO2000
Vaginal
Gel is Ineffective in Preventing HIV Infection: Results of the
MDP301 Phase III Microbicide Trial
- Association
of
Expanded HAART Coverage with a Decrease in New HIV Diagnoses,
Particularly among Injection Drug Users in British Columbia, Canada
- New
Resistance
Mechanisms and Detection Methods
- A
Novel
Peptide-based HIV-1 Inhibitor Selects for pol Mutations
L100I/K102R/K103N in Primary Human Lymphocytes
- A
New
Mechanism Enhancing the Ability of HIV to Escape from
Antiretrovirals
- Herpes
Simplex
Virus Type 2 Suppressive Therapy with Acyclovir or Valacyclovir
Does Not Induce Specific HIV-1 Resistance in HSV-2/HIV-1
Dually-infected Persons
- Population-based
Sequencing
of the V3-loop Is Comparable to the Enhanced Sensitivity
Trofile Assay in Predicting Virologic Response to Maraviroc of
Treatment-naïve Patients in the MERIT Trial
- New
Insights
into Retroviral Pathogenesis
- Plasma
Levels
of WFDC1/ps20, a Novel Viral Permissivity Factor in CD4 T
Lymphocytes, Correlates Directly with CD4 T Cell Count in Chronic HIV-1
Infection
- Tryptophan
Catabolism
by Indoleamine 2,3-Dioxygenase Alters the Balance between
Th17 and Regulatory T Cells in Progressive HIV Disease
- Sooty
Mangabeys
CD4+ Central Memory T Cells Are Relatively Resistant to CCR5
Expression and SIV Infection: A Key Mechanism for AIDS Resistance?
- Identification
of
a Novel CCR5 Mutation Common in Sooty Mangabeys Indicates that Entry
by SIVsmm Occurs through Alternative Entry Pathways in Addition to CCR5
- Differences
in
HIV Burden throughout the Gut of Patients on Suppressive ART:
Implications for HIV Persistence
- The
Genetic
Diversity of HIV-1 in Plasma Persists Despite Suppression with
ART
- Population
Decline
in a Chimpanzee Community with a High Prevalence of SIVcpz
Infection
- HIV-1
Replication
and Immune Dynamics Are Impacted by Raltegravir
Intensification of HAART-suppressed Patients
- Raltegravir
Intensification
in Antiretroviral-treated Patients Exhibiting a
Suboptimal CD4+ T Cell Response
- TB
Prevention
and Treatment and Complications of HIV and ART
- Effectiveness
of
Isoniazid Preventive Therapy in Reducing Mortality in Patients on
ART
- Efficacy
of
a 6-month vs a 36-month Regimen for Prevention of Tuberculosis in
HIV-infected Persons in India: A Randomized Clinical Trial
- Randomized,
Placebo-controlled
Trial of 6 vs 36 Months Isoniazid TB Preventive
Therapy for HIV-infected Adults in Botswana
- Randomized
Trial
of a 6-month Punctuated Course of ART in Ugandan HIV+ Adults with
Pulmonary TB and CD4 >350
- Bone
and
Limb Fat Outcomes of ACTG A5224s, a Substudy of ACTG A5202: A
Prospective, Randomized, Partially Blinded Phase III Trial of ABC/3TC
or TDF/FTC with EFV or ATV/r for Initial Treatment of HIV-1 Infection
- Chronic
Kidney
Disease and Exposure to ART in a Large Cohort with Long-term
Follow-up: The EuroSIDA Study
- Progress
and
Problems in ART Rollout
- Pre-treatment
Mortality
and Probability of Starting ART in Patients Enrolled in the
Free State ARV Program, South Africa: Implications for Treatment
Guidelines
- Trends
in
Enrollment Characteristics of Patients at a Large HIV Clinic in
Kenya 2003 to 2008: Implications for ART Guidelines
- Immune
Restoration
over 5 Years on ART among Patients Initiating Treatment
with Advanced Immune Deficiency in the DART Trial in Uganda and
Zimbabwe
- Comparison
of
Immunologic and Virologic Failure Criteria in a Large ART Program in
Nigeria
- TD:
Impact
of KIR/HLA on HIV Infection
- Next-generation
Sequencing
for HLA Typing and MHC Sequence Interrogation for Host
Genetics of HIV Infection
- Effects
of
Killer Immunoglobulin-like Receptor and Human Leukocyte Antigen
Genes on Heterosexual HIV-1 Transmission
- HLA
Class
II Allele DRB1*1303 Is Associated with Reduced Viral Loads in 2
Independent Cohorts of Different Ethnicity and HIV Clades of Infection
- NK
Receptor-HLA
Ligand Requirements for Increased Polyfunctional Potential
in NK Cells from Individuals Carrying KIR3DL1*h/*y+ HLA-B*57
- HLA
and
HIV: Current Perspective
- TD:
Improving
Estimates of HIV-1 Incidence
- Improved
Precision
of Cross-Sectional HIV Incidence Testing Using a Multi-assay
Algorithm that Includes BED and an Avidity Assay with Modified Assay
Cut-offs
- Development
of
a Bead-based, Multiplex Assay for Estimation of Recent HIV-1
Infection
- Antibody
Avidity-based
Assay for Identifying Recent HIV-1 Infections Based on
Genetic Systems TM ½ plus O EIA
- Concordance
of
Recent HIV Infection between 3 STARHS Assays Is Not Dependent on
Patient Characteristics
- Performance
of
BED-CEIA and Avidity Index Assays in a Sample of ART-naïve,
Female Sex Workers in Kigali, Rwanda
- TD:
Viral
Co-factors and Cellular Restrictions
- Identification
and
Characterization of Key Cellular Factors Required for HIV
Infectivity and Trafficking
- Activity
of
Ancestral Restriction Factors against Ancient Retroviruses
- Direct
Restriction
of Virus Release and Incorporation of the
Interferon-induced Protein BST-2 into HIV-1 Particles
- Contribution
of
RING Domain to Retrovirus Restriction by TRIM5a Depends on
Combination of Host and Virus Species
- Association
of
Potent Anti-HIV-1 APOBEC3 Proteins with 7SL and Viral Genomic RNA
- Evidence
for
an Activation Domain at the Amino-terminus of SIV Vpx
- TD:
HIV
Drug Resistance in Breastfeeding Infants Exposed to ART
- Transmission
of
NVP-resistant HIV-1 to Infants by Breastfeeding Observed after
Maternal sdNVP
- Comparison
of
NVP Resistance among HIV-infected Infants Who Received Extended NVP
plus ZDV Prophylaxis vs Extended NVP Prophylaxis Alone: The PEPI-Malawi
Study
- Delayed
Clearance
of High-frequency NVP-resistant Viremia in the First Year of
Life in HIV-infected Infants Who Received Extended NVP for Prevention
of Breast-milk Transmission: Implications for Early Therapy
- Multi-class
Drug
Resistance Arises Frequently in HIV-infected Breastfeeding Infants
Whose Mothers Initiate HAART Postpartum
- TD:
Progression
of Atherosclerosis: Role of Inflammation and T Cell
Activation
- Earlier
Initiation
of Antiretroviral Therapy in HIV-Infected Individuals is
Associated with Reduced Arterial Stiffness
- Inflammation
is
Associated with Endothelial Dysfunction among Individuals with
Treated and Suppressed HIV Infection
- T
Cell
Senescence and T Cell Activation Predict Carotid Atherosclerosis
in HIV-infected Women
- Rates
and
Determinants of Progression of Carotid Artery Intima-media
Thickness and Coronary Artery Calcium in HIV Infection
- Understanding
the
Variability of Drug Response
- The
Pharmacokinetics
of Body Compartments: Drug Transporters and
Penetration
- Pharmacogenetics—Upcoming
Applications
to Patient Care
- Clinical
Pharmacology
in Resource-limited Countries
- Clinical
Pharmacokinetics
and Pharmacodynamics of Integrase Inhibitors
- Challenges
in
HIV Prevention
- Social
and
Structural Barriers to HIV Prevention: Emerging Lessons from the US
- Gender
and
HIV/AIDS in Southern Africa
- Challenges
of
Alcohol Use for HIV Prevention
- The
Impacts
and Legacy of HIV Exceptionalism
- HIV
Replication:
In and Out of the Cell
- New
Views
of HIV Entry
- The
Virology
and Immunology of HIV Cell-to-Cell Transfer
- HIV-1
RNA
Trafficking, Dimerization, and Encapsidation
- Hexameric
Assembly
of a Restricting TRIM5a Protein: Implications for Molecular
Recognition of Retroviral Capsids
- Long-term
Complications:
Hearts and Bones
- Rates
of
Cardiovascular Disease Following Smoking Cessation in Patients with
HIV Infection: Results from the D:A:D Study
- Rapid
Progression
of Atherosclerosis at the Carotid Bifurcation Is Linked to
Inflammation in HIV-infected Patients
- Progression
of
Carotid Intima-Media Thickness in a Contemporary HIV Cohort
- Triglycerides
and
the Risk of Myocardial Infarction in the D:A:D Study
- Higher
and
Increasing Rates of Fracture among HIV-infected Persons in the HIV
Outpatient Study Compared to the General US Population, 1994 to 2008
- HIV-infection
and
Fragility Fracture Risk among Male Veterans
- Fracture
Rates
Are Not Increased in Younger HIV+Women
- Uridine
Supplementation
in the Management of HIV Lipoatrophy: Results of ACTG
5229
- Mouse
to
Man? XMRV and Human Disease
- Mouse
to
Man? XMRV and Human Disease
- HCV
Entry:
Unlocking the Door
- Hepatitis
C
Virus Entry: Unlocking the Door
- New
Insights
into Transmission and Acute Infection
- A
Finite
Course of ART during Early HIV-1 Infection Modestly Delays Need
for Subsequent ART Initiation: ACTG A5217, The SETPOINT Study
- Profound
Depletion
of HIV-1 Transcriptionally Active PBMC by Early cART during
Primary HIV-1 Infection but Not by Treatment during Chronic Infection:
Results of the Zurich Primary HIV Infection Study
- ART
and
Risk of Heterosexual HIV-1 Transmission in HIV-1 Serodiscordant
African Couples: A Multinational Prospective Study
- Sex
and
Race Influence Clinical Presentations and Outcomes following
Primary HIV-1 Infection
- HIV-1
Enters
in the Seminal Tract by Multiple Mechanisms and in a
Cytokine-rich Environment
- Neisseria
gonorrhoeae
Enhances HIV-1 Infection of Primary Resting CD4+ T Cells
through TLR2 Activation
- Monospecific
Expansion
of SIVmac251 during Acute Infection May Mask Multiple
Transmitted Virus Variants Revealed during the Chronic Phase
- Lack
of
Post-Peak Decline of Viremia and Accelerated Course of SIVmac251
Infection in Rhesus Macaques Undergoing an Antibody-mediated CD4+ T
Cell Depletion Prior to Infection
- Virus–Host
Interaction:
HIV and XMRV
- Ancient
Evolutionary
Changes to Tetherin Shaped Vpu and Nef Functions in HIV-1
Adaption to Humans
- Compensatory
Genetic
Changes Acquired by a nef-deleted Serially Passaged SIV Vaccine
Strain Confer Resistance to Tetherin
- HIV-1
Vpu
Transmembrane Domain Mutants: Enhancement of Virion-release
Correlates with Down-regulation of BST-2, Is Independent of Ion Channel
Activity, and Occurs from a Post-endoplasmic Reticulum Compartment
- Use
of
LEDGF/p75 Fusion Proteins to Retarget Lentiviral Integration Outside
of Genes
- Direct
Cell-to-Cell
HIV Transfer Is Insensitive to ART at High Drug
Concentrations
- Cellular
Determinants
Required for Infection of XMRV, a Novel Retrovirus
Associated with Human Familial Prostate Cancer
- Host
Regulation
of XMRV in Prostate Cancer
- Prevalence
of
Xenotropic Murine Leukemia Virus in Prostate Cancer
- Organ
and
Cell Lineage Dissemination of XMRV in Rhesus Macaques during Acute
and Chronic Infection
- XMRV:
Examination
of Viral Kinetics, Tissue Tropism, and Serological Markers
of Infection
- Treatment
Outcomes
in Women and Children
- Effect
of
Hormonal Contraceptive Use on Time to AIDS or Death in Female HIV
Seroconverters in Rakai, Uganda
- Efficacy
of
ART with NVP+TDF/FTC vs LPV/r+TDF/FTC among
Antiretroviral-naïve Women in Africa: OCTANE Trial 2/ACTG A5208
- NNRTI-resistant
Variants
Detected by Allele-specific PCR Predict Outcome of
NVP-containing ART in Women with Prior Exposure to sdNVP: Results from
the OCTANE/A5208 Study
- Co-factors
for
HIV Incidence during Pregnancy and the Postpartum Period
- Repeat
HIV
Testing in Labor and Delivery as a Standard of Care Increases ARV
Provision for Women Who Seroconvert during Pregnancy
- 12-Month
Follow-up
of the SWEN Randomized Controlled Trials: Differential Impact
of Infant Extended-dose NVP by CD4 Count on Prevention of HIV
Transmission via Breastfeeding, and Infant Mortality
- National
Scale-up
of Early Infant Diagnostic Testing for HIV in Uganda
- Plasma
Frequencies
of Nevirapine Resistance Influence Virologic Responses to
Nevirapine Maintenance Therapy in Single-Dose Exposed HIV-infected
Children Initially Treated with Lopinavir HAART
- Treatment
Outcomes
among HIV-infected Infants and Young Children following
Modifications to Protease Inhibitor-based Therapy Due to TBTreatment
- Interim
Results
from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet
(OCT) Formulation in Children 6 to 11 Years
- Hepatitis
C:
Transmission, Outcomes, and Treatment
- The
Interleukin
28B Gene and HCV Recovery
- Association
of
IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected
Individuals
- Genetic
Variation
in IL28B and Treatment-induced Clearance of HCV in HCV/HIV
Co-infected Patients
- Strong
Association
of a Single Nucleotide Polymorphism Located Near the
Interleukin-28b Gene with Response to Hepatitis C Therapy in HIV/HCV
Co-infected Patients
- Baseline
Liver
Disease Is Independently Associated with Risk of Death among 631
HIV/HCV Co-infected Adult with Histologic Staging
- Sustained
Virological
Response to Interferon plus Ribavirin Reduces HIV
Progression and Non-liver-related Mortality in Patients Co-infected
with HIV and HCV
- Survival
of
HCV in Syringes: Implication for HCV Transmission among Injection
Drug Users
- HCV
Transmission
and Diversification in Infected Subjects Analyzed by Deep
Sequencing
- Ultra-deep
Sequencing
Analysis Demonstrates Pre-existence of HBV Resistance
Substitutions at Baseline in Patients Who Subsequently Develop Clinical
Resistance
- TD:
Antiretroviral
Agent Penetration into Genital Secretions
- Raltegravir
Concentrations
in the Cervicovaginal Compartment Exceed the Median
Inhibitory Concentration in HIV-1-infected Women Treated with a
Raltegravir-containing Regimen: DIVA 01 Study
- Steady-state
Raltegravir
Penetration in Seminal Plasma of Healthy Volunteers
- Darunavir
Concentrations
in Seminal Plasma in Patients Receiving
Darunavir/ritonavir (DRV/r) Monotherapy: A MONOI-ANRS 136 Substudy
- Darunavir
(DRV)
Concentrations Exceed the Protein-corrected (PC) EC50 for Wild
Type HIV in the Semen of HIV-1 Positive Infected Men
- Maraviroc
Levels
in Cerebrospinal Fluid (CSF) and Seminal Plasma from
HIV-Infected Patients
- TD:
NK
Cells and ADCC: Linking Innate and Adaptive Immunity
- Evidence
of
HIV Viral Escape from NK Cell-mediated ADCC
- Purification
and
Evaluation of HIV-specific ADCC Antibodies
- Exclusion
of
KIR+ NK Cells from Lymph Nodes during HIV-1 Infection May Represent
a Novel Mechanism by which the Virus Escapes Innate Immune Control
- Differential
Homing
Potential of NK Cell Subsets to Lymphoid and Peripheral Tissues
during HIV Infection
- Natural
Killer
Receptor Genotypes in HIV-infected Patients Lacking CD4 Recovery
on Long-term ART
- TD:
Swine
Flu Meets HIV
- New
Swine
Origin Influenza A (H1N1)v in HIV-Infected Patients During the
2009 Outbreak in Mexico City
- LB 2009
H1N1
Virus Infection in HIV+ Adults
- LB Clinical
Features
of Subjects Infected with HIV and H1N1 Influenza Virus
- LB Immunogenicity
of
One Dose of Influenza A H1N1v 2009 Vaccine Formulated with and
without AS03A-Adjuvant in HIV+ Adults: Preliminary Report of the ANRS
151 Randomized HIFLUVAC Trial
- LB Low
Rate
of Immunoresponse to the Novel Split Virion, Inactivated,
Adjuvanted Pandemic H1N1 Influenza Vaccine in HIV-1-infected Patients
- LB Poor
Immunogenicity
of the H1N1 2009 Vaccine in Well Controlled HIV-infected
Individuals: Interim Results of an Immunogenicity Trial
- LB Elevated
2009
H1N1 Antibody Titers in HIV-infected and Uninfected Women in the
US: A Sero-study, March 1 to September 30, 2009
- LB Safety
of
an Inactivated H1N1 2009 H1N1 Vaccine in HIV-1-infected Pregnant
Women, IMPAACT P1086
- LB 2009
H1N1
Immunization in HIV-1 Perinatally Infected Children and Youth
- TD:
Impact
of Treatment Intensification on HIV Reservoirs and Immune
Activation
- Effect
of
Raltegravir-containing Intensification on HIV Burden and T Cell
Activation in the Gut of HIV+ Adults on Suppressive ART
- Raltegravir
Intensification
Does Not Reduce Persistent HIV-1 Viremia in
Treatment-experienced Patients
- No
Evolution
of HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of
Raltegravir-containing Therapy in Patients with Controlled Viremia: A
Sub-study of the Randomized EASIER-ANRS 138 Trial
- Intensification
of
HAART through the Addition of Enfuvirtide in Naive HIV-infected
Patients with Severe Immunosuppression Does Not Improve Immunological
Response: Results of a Prospective Randomized Multicenter Trial (APOLLO
- ANRS 130)
- The
Antiviral
and Immunological Effects of Intensification of Suppressive
ART with Maraviroc, a CCR5 Antagonist
- Effect
of
the Intensification with a CCR5 Antagonist on the Decay of the HIV-1
Latent Reservoir and Residual Viremia
- Maraviroc
Intensification
for Suboptimal CD4+ Cell Response Despite Sustained
Virologic Suppression: ACTG 5256
- TD:
Renal
Disease: Mechanisms and Outcomes
- Factors
Associated
With Decreased Glomerular Filtration Rate (GFR) in
HIV-infected Adults Enrolled in the MTCT-Plus Initiative in Seven
Sub-Saharan African Countries
- Low
CD4
Cell Count and Impaired Renal Function Are Independent Risk Factors
for ARF in HIV Infected Patients
- HAART
is
Associated with Improved Kidney Function in Patients with Impaired
Kidney Function at Baseline but Was Associated with Slight Worsening of
Kidney Function in Patients with Normal Baseline Kidney Function
- Intrarenal
Inflammation
Contributes to HIV-Related Proteinuria
- The
Value
of Urine Protein/Creatinine and Albumin/Creatinine Ratios in
Assessing Renal Disease in HIV Infection
- Neuropathogenesis:
Clinical
Correlates and Impact of ART
- HIV
Treatment
Modulates Global Resting Cerebral Blood Flow in HIV+ Subjects
- Correlates
of
CSF Viral Loads in 1221 Volunteers of the CHARTER Cohort
- Correlates
of
Epidermal Nerve Fiber Density in HIV-infected Individuals without
Neuropathy prior to Initiation of Potent ART
- An
SIV
Macaque Model of HIV-induced Peripheral Neuropathy
- HIV
Subtype
A Is Associated with Impaired Neuropsychological Performance
Compared to Subtype D in ART-naïve Ugandan Children
- Increased
Spontaneous
Shedding of Soluble gp120 by HIV in Brain from Patients
with Dementia
- Treponema
pallidum
Strain Type Is Associated with Neurosyphilis
- New
Insights
into Mechanisms of T Cell Protection
- NK
Cell
Function
- Vaccine-induced
Cellular
Responses against HIV
- New
Insights
into Mechanisms of T Cell Protection against SIV
- The Future
of HIV Therapeutic Research—The Treatment Agenda
- HIV
Cure:
Is
it Realistic?
- Limitations
of
Current
Therapies in Developed Countries
- Beyond
First-line
Therapy
in Resource-limited Settings
- Future
Directions
in
HIV/TB Research
- Cellular
Restrictions:
APOBEC
- Intrinsic
Restriction
Activity
by APOBEC1 against the Mobility of Autonomous
Retrotransposons
- HIV-1
Virion
Misincorporation
as an Alternative Escape Strategy from APOBEC3H
Restriction
- A
Single
Amino
Acid Difference in Human APOBEC3H Variants Determines
HIV-1 Vif Sensitivity
- Structure-guided
Mutagenesis
of
APOBEC3G Reveals Critical Lysine Residues for HIV-1
Vif-mediated Ubiquitination/Degradation
- Long-term
Restriction
of
HIV-1 by Human APOBEC3F Exerts Unique Selective Pressure
for the Restoration of Vif Function
- Impact
of
Cell
Types on the APOBEC3G-Induced G-to-A Hypermutation Rate in
HIV-1 DNA Revealed by Massively Parallel Pyrosequencing
- HIV-1
Inter-subtype
Vif
Variability Affects APOBEC-3G-mediated Host
Restriction
- Impact
of
Structural
Genomic Variation in the APOBEC3 Locus on Susceptibility
to HIV Infection
- Cellular
Restrictions:
TRIM5
and Novel Factors
- Generation
of
Human
TRIM5alpha Mutants with Anti-HIV-1 Activity
- Viral
and
Host
Determinants for the Restriction of HIV-2/SIVmac by Rhesus
Monkey TRIM5a
- A
Role
for
Sumoylation in TRIM5 Protein-mediated Restriction?
- Molecular
Characterization
of
CPSF6-358 Domains Required for Antiviral Function
- Adenosine
Deaminase
1
Is a Novel Anti HIV-1 Cellular Factor
- Cellular
Restrictions:
Tetherin
and Vpu
- HIV-1
Vpu
Internalizes
Cell-surface BST-2/Tetherin and Leads It to Lysosomes
- BCA2/Rabring7
Promotes
Tetherin-dependent
HIV-1 Restriction
- No
Species-specific
Co-factors
for HIV-1 Tethering Function of Human
BST-2/Tetherin
- No
Evidence
for
a Restriction of Retrovirus Release by Calcium-Modulating
Cyclophilin Ligand
- HIV-1’s
Vpu
and
TASK Proteins Inhibit HIV-1 Transcription
- Viral
Co-factors
and
Cellular Restrictions
- Identification
and
Characterization
of Key Cellular Factors Required for HIV
Infectivity and Trafficking
- Activity
of
Ancestral
Restriction Factors against Ancient Retroviruses
- Direct
Restriction
of
Virus Release and Incorporation of the
Interferon-induced Protein BST-2 into HIV-1 Particles
- Contribution
of
RING
Domain to Retrovirus Restriction by TRIM5a Depends on
Combination of Host and Virus Species
- Association
of
Potent
Anti-HIV-1 APOBEC3 Proteins with 7SL and Viral Genomic RNA
- Evidence
for
an
Activation Domain at the Amino-terminus of SIV Vpx
- New
Insights
into
Virus Replication: Co-factors and Virus Entry
- Constraints
on
HIV-1
Diversity from Protein Structure
- Structure
Determination
of
Unliganded, Intact HIV-1 gp41 Membrane-Proximal
External Region
- Production
of
Low
Titer of Infective HIV-1 Pseudoparticles with a Deglycosylated
GP140 Construct Lacking Transmembrane Domain
- Cell-to-Cell
Spread
of
HIV Enhances Multiplicity of Infection
- Cell
Superinfection
Accelerates
HIV-1 Replication and Bypasses Integration
through Viral Complementation
- Multidimensional
Quantitative
Analysis
of HIV-1 Entry Efficiency
- HIV-1
Adapts
to
the Loss of a Vital RNA Dimerization Element: Implication to
RNA Interference-Based Antiviral
- Virus–Host
Cell
Interaction:
Studies on Macrophages
- 1,25-dihydroxycholecalciferol
Triggers
Autophagy
in Human Macrophages that Inhibits Productive HIV-1
Infection
- Contribution
of
beta-Integrins
to HIV-1 Infection in Macrophages
- HIV-1
ssRNA40
Induces
Interferon-alpha Expression Plasmacytoid Dendritic
Cells through Activating Autophagy
- HIV
Down-regulates
the
Transcription of Interferon-stimulated Genes in
Macrophages
- Variation
in
V1V2
and on the Flanks of the CD4 Binding Loop Affect HIV-1 R5
Envelope Infectivity and Macrophage Tropism
- Identification
and
Characterization
of HIV-1 Small Noncoding RNA in Primary
Macrophages and Peripheral Blood Mononuclear Cells
- Discovery
of
Common
Genetic Variants Associated with in vitro HIV-1 Replication
in Monocyte-derived Macrophages
- Therapeutic
Strategies
for
Nef
- Llama
Antibody
Fragment
for Inhibition of the HIV-1 Nef Protein
- Chemical
Inhibition
of
HIV-1 Nef-mediated MHC-I Down-regulation by Targeting
Multi-Kinase Complex Assembly
- Virus–Host
Cell
Interaction:
Impact of Virus on Host Cell Processes
- HIV-1,
Host
Interaction
Patterns: Interpreting a Complex Network
- Tat
Association
with
the PP2A and PTEN Promoters Is the Key Event in the
Transcriptional Activation of FOXO3a-dependent Genes Related to
Apoptotic Pathways in HIV-infected CD4+ T Cells
- HIV-1
Transactivator
Protein
Regulates IFNg-Receptor b/JAK2-mediated IFN-g
Signaling
- CD44
Capping
and
c-Src Signaling Enhance HIV-1 Infection in T Cells
- Post-entry
Events
of
Efficient R5 vs Inefficient X4 HIV-1 Replication in Primary
CD4+ T lymphocytes, a Transcriptome Analysis
- HMGB1
and
Bacterial
Components Synergistically Induce HIV-1 Replication in
vitro
- Mutational
Analysis
of
the HIV Tat Protein and Its Ability to Down-regulate CD127
on CD8 T Cells
- Expression
and
Regulation
of CXCL12 by the Protein Tax of HTLV-1
- Nef
Produced
from
Unintegrated HIV-1 DNA Can Down-regulate CXCR4 and CCR5
- An
Immunosuppressive
Role
for HIV Nef Protein via Regulation of PD-L1/2
Expression on Antigen Presenting Cells
- Interactions
between
the
Cellular RNAi Pathway and HIV-1 Replication
- New
Insights
into
Virus Replication: Integration, Assembly, and Viral
Latency
- Novel
Host
Factors
in HIV Integration Site Targeting
- Correlation
Analysis
of
LEDGF/p75-Bound Sequences and HIV Integration Sites
- Influence
of
Host
Gene Transcriptional Level and Orientation on HIV-1 Latency in
Primary Cells
- Distinct
H3K9
and
H3K27 Modification Patterns in HIV-1 Latent Cells
- Assessment
of
Epigenetic
Modifications as a Direct Consequence of HIV Infection in
Primary CD4+ T cells
- Deoxynucleoside
Treatment
Remedies
HIV-1 LTR Attrition in Quiescent CD4 Tcells
- Establishment
of
Latency
in Naïve and Central Memory T Cells in a Primary CD4
Cell Model
- Myeloid
DC
Induce
HIV-1 Latency in Resting CD4+ T Cells in vitro
- Identification
of
Natural
Compounds that Reactivate Expression of Latent HIV-1
- The
Histone
Deacetylase
Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5
Expression on CD4+ T Cells and Monocytes and Is Superior to Valproic
Acid for Latent HIV-1 Expression in vitro
- Expression
and
Characterization
of Recombinant Human ESCRT-I Complex
- Viral
Decay
Dynamics
with ART
Stage-dependent
Inhibition
of
HIV-1 in vitro and Implications for Raltegravir
- Longer
Phase
I
Viral Decay in Treatment-naïve Patients Receiving
Raltegravir-based ART: Preliminary Results from ACTG 5248
- Monotherapy
with
Integrase,
Reverse Transcriptase, and CCR5 Inhibitors Lead to
Progressively Longer Delays before HIV RNA Reduction in vivo
- HIV
Evolution
in
vivo
- Combined
ART
and
Immune System Pressure Leads to in vivo HIV-1 Recombination
with Ancestral Viral Genomes
- Biological
Characterization
of
HIV-1 Isolated from Purified Human Monocytes
- Use
of
a
High-resolution Melting Assay to Evaluate HIV Gag Region Diversity
in HIV-infected Adults with Different Stages of HIV Infection
- Sequencing
and
Functional
Analysis of Rev and RRE in Longitudinal Patient Samples
- Quantitative
Deep
Sequencing
Reveals Hidden Lineages and Shifts of Viral Population
in Archived and Replicating HIV-1 Genomes
- Evolution
of
HIV
Co-receptor Usage
- CD4+
T
Cell
Turnover Is Related to Chemokine Receptor Expression and HIV
Viral Co-receptor Tropism
- Sensitivity
to
CCR5
and Fusion Inhibitors Decreases over the Course of HIV-1
Infection
- Adaptation
to
Use
Low Levels of the CD4 Receptor is an Early Event in the Process
of Coreceptor Switching in R5 SHIV-infected Rapid Progressors
- Evolution
of
Env
Protein and Co-receptor Usage during Pregnancy in Women Infected
with B vs Non-B HIV-1 Subtypes
- X4
Emergence
in
a Seropositive R5 SHIVSF162P3N-infected Macaque and in a
Macaque Infected with Its Molecular Clone
- Ultra-deep
Pyrosequencing
Captured
Low Frequency CXCR4 Virus Populations
Co-archived with CCR5 Virus in Peripheral Blood Lymphocytes from
HIV-infected Therapy-naïve Children
- Detection
of
Predicted
CXCR4-using HIV-1 Variants in Longitudinally Obtained
Paired Plasma and Peripheral Blood Mononuclear Cells Samples Using
454-Sequencing
- Prediction
of
X4-tropic
HIV from Proviral Envelope Sequence in Patients with
Suppressed Viral Load on ART
- Prevalence
of
CXCR4-using
Subtype C HIV-1 Infection among Treatment-naive Women:
Results from the Mashi Study
- Impact
of
Treatment
Intensification on HIV Reservoirs and Immune Activation
- Effect
of
Raltegravir-containing
Intensification on HIV Burden and T Cell
Activation in the Gut of HIV+ Adults on Suppressive ART
- Raltegravir
Intensification
Does
Not Reduce Persistent HIV-1 Viremia in
Treatment-experienced Patients
- No
Evolution
of
HIV-1 Total DNA and 2-LTR Circles after 48 Weeks of
Raltegravir-containing Therapy in Patients with Controlled Viremia: A
Sub-study of the Randomized EASIER-ANRS 138 Trial
- Intensification
of
HAART
through the Addition of Enfuvirtide in Naive HIV-infected
Patients with Severe Immunosuppression Does Not Improve Immunological
Response: Results of a Prospective Randomized Multicenter Trial (APOLLO
- ANRS 130)
- The
Antiviral
and
Immunological Effects of Intensification of Suppressive
ART with Maraviroc, a CCR5 Antagonist
- Effect
of
the
Intensification with a CCR5 Antagonist on the Decay of the HIV-1
Latent Reservoir and Residual Viremia
- Maraviroc
Intensification
for
Suboptimal CD4+ Cell Response Despite Sustained
Virologic Suppression: ACTG 5256
- HIV
Reservoirs
- Quantification
of
Persistent
Viremia in Cerebrospinal Fluid and Plasma: Initial
Experience in a Raltegravir Intensification Study
- Naïve
CD4+
Cells
Can Contribute to Viral Reservoirs in Patients with HIV
- Longitudinal
Study
of
HIV Variant Compartmentalization in Patients Initiating HAART
during Primary Infection
- Analysis
of
HIV
DNA Molecules in Single Infected Cells from Recently and
Chronically Infected Patients
- HIV–Cell
Interaction
in
vivo
- HIV
Infection
in
Rhesus Macaques Significantly Reduces the Proliferation of
Tonsillar CD21+CD27+ Memory B Cells
- Regulation
of
SIVagm-induced
Production of IFN-alpha and Interferon Stimulated
Genes in African Green Monkey Cells
- Productive
Infection
in
Macaques with a Clade B Dual RT-Env SHIV
- Lymph
Node
Follicular
Interferon-alpha Is Related to Reduced Virus-producing
Cells, but Does Not Explain Sex Differences in HIV-1 Infection
- Sex
Differences
in
Innate Immunity during HIV Infection: Study of Dendritic
Cells and IFN-a Response
- HLA-DR+CD38+
Lymphocytes
Are
Preferential Targets of HIV-1 both in vitro and in vivo
- Determinants
of
Slow
Progression of HIV Disease
- Reduced
Immune
Activation
in Course of HTLV-2 Infection Exerts a Protective
Role on HIV-1 Replication
- Gut-homing
Potential
of
HIV-specific CD4+ and CD8+ T Cells in HIV-infected
Subjects with Slow Disease Progression
- Sustained
CD4
Counts
and Preserved Functional CD8 T Cell Responses are Key
Determinants of Natural Control of HIV-1 Infection
- Viral
Evolution
in
HIV-1 Infection Controllers
- Determining
the
Role
of APOBEC3 in the Interferon-a Suppression of HIV-1 in vivo
- Low
Replicative
Capacity
of HIV-1 Envelopes Derived from the Viruses
Present in a Super-infected Elite Suppressor Patient
- Disease
Progression
after
Intrasubtype Superinfection in an HLA-B57+
Asymptomatic LTNP Initially Infected with a nef-defective HIV-1 Strain
- Biomarkers
of
HIV
Disease and Death
- Plasma
Levels
of
Soluble CD14 Predict Mortality in HIV Infection
- Coagulation
and
Inflammation
Biomarkers Correlate with Disease Progression in SIV
Infections
- C-reactive
Protein
as
an Indicator of Global Immune Activation and Disease
Progression in HIV-1-infected Ugandan Individuals
- Impact
of
CD8+
T Cell Activation on CD4+ T Cell Recovery and Mortality in
HIV-infected Ugandans Initiating ART
- HIV-1
Residual
Viremia
Correlates with Persistent T Cell Activation in Poor
Immunological Responders to Combination ART
- Concomitant
CD38
Mean
Fluorescence Intensity on CD8+ T Cells Predicts Rise or
Decline of HIV Viral Load in Response to Treatment Interruption or ART
Initiation in Chronically HIV-1-infected Individuals
- Plasma
Levels
of
LPS and HMGB1 Are Elevated in HIV-1 and Reduced after 2 Years
Effective ART
- An
Imbalance
between
Antifibrotic and Profibrotic Factors Were Associated
with Lymphoid Tissue Fibrosis in HIV Infection
- Reversing
B
Cell
Exhaustion Associated with Chronic HIV Infection
- Expression
of
a4B7
Integrin on Peripheral Blood T Lymphocytes Correlates with
Intestinal CD4 T Cells in HIV Infection
- CD4
T
Cell
Functions and Immune Recovery
- Role
of
Baseline
CD4 and Viral Load in CD4 Increase in Patients Initiating
HAART with CD4< 200 Cells/muL
- Poor
CD4 T Cell Recovery in Virologically Suppressed HIV-infected
Patients Is Determined by High CD4 T Cell Destruction, and Predicted by
Nadir CD4 T Cell Count. Clinical Implications
- Effect
of
Ongoing
Viral Load Changes on the Rate of CD4 Count Depletion during
Untreated HIV Infection
- T
Cell
Senescence
and Proliferation Defects Persist in Treated
HIV-infected Individuals Maintaining Viral Suppression and Are
Associated with Poor CD4+ T Cell Recovery
- Increased
Thymic
Production
of Regulatory T Cells in HIV-infected Patients:
Contribution of the Thymus to the Maintenance of Treg Levels
- Preferential
Depletion
of
Peripheral Memory CD4+CD73+ T Cells by HIV-1 Infection
- Gag-specific
CD39+OX40+CD25+
and
CD39-OX40+CD25+ Regulatory and Effector T Cell
Frequencies Are Inversely Correlated in HIV-infected Patients
- Dysfunction
of
HIV-specific
CD4+ T Cells Is Associated with Elevated Concurrent
Expression of Multiple Inhibitory Receptors
- HIV
Controller
CD4+
T Cells Respond to Minimal Amounts of Gag Antigen Due
to High TCR Avidity
- What
Monkey
Models
Can Teach Us about HIV Infection
- CCR5
Blockade
Alters
the in vivo Trafficking of CCR5+ and CD25+ T Cells in
Healthy, SIV-uninfected Rhesus Macaques
- SIVmac239-mediated
Down-modulation
of
Integrin alpha4beta7 on Infected Cells
- Systems
Biology
Analysis
of CD8 Lymphocyte Depletion in SIV-infected Rhesus
Macaques
- Chronic
SIV
Infection
Perturbs the Functional and Phenotypic Heterogeneity of
Macaque NK Cell Subsets
- Natural
Killer
T
Cells in Sooty Mangabeys Are Phenotypically Distinct from
Asian Macaques and Are Maintained following SIV Infection
- Nonpathogenic
SIV
Infection
of Sooty Mangabeys Induces an LPS-specific Reduction in
Monocyte Inflammatory Cytokine Production
- NK
Cells
and
ADCC: Linking Innate and Adaptive Immunity
- Evidence
of
HIV
Viral Escape from NK Cell-mediated ADCC
- Purification
and
Evaluation
of HIV-specific ADCC Antibodies
- Exclusion
of
KIR+
NK Cells from Lymph Nodes during HIV-1 Infection May Represent
a Novel Mechanism by which the Virus Escapes Innate Immune Control
- Differential
Homing
Potential
of NK Cell Subsets to Lymphoid and Peripheral Tissues
during HIV Infection
- Natural
Killer
Receptor
Genotypes in HIV-infected Patients Lacking CD4 Recovery
on Long-term ART
- New
Markers
of
Immune Dysfunction and Recovery
- Role
of
Microbial
Translocation and Immune Hyperactivation in Disease
Progression of HIV+ Patients with Preserved CD4 Count in the Absence of
ART
- Role
of
the
Stromal Cell-derived Factor-1-1 Allelic Variant SDF-1 3’A in
HIV-1 Disease Progression
- Higher
Levels
of
D-dimer, C-reactive Protein, Hyaluronic Acid, and IL-6 before
Initiation of ART Are Associated with AIDS, IRIS, or Death among
ART-naive Patients with a Good Virologic Response to Initial ART
- Elevated
Serum
IL-7
Levels, Expansion of Memory CD4+ T Cells, Augmented T Cell
Activation and Inflammation in Patients Developing IRIS after ART
Initiation
- HIV
Regulates
IL-23
and IL-27 Production in Monocytic Cells
- CTL
Epitopes
and
Immune Control
- TCR
Repertoire
Diversity
in Virus-specific CD8 T Cells
- CTL
Responses
to
HIV Gag p24 Can Be Detected in HIV Non-controllers but Are
of Low Functional Avidity, Lack Cross-reactivity Potential, and Show
Slow in vitro Response Rates to Antigen Stimulus
- Identification
of
CTL
Selection Pressures Associated with HIV-1 Fitness Defects Using
a Recombinant Virus Screening Approach
- Examination
of
the
Role of Epitope Presentation Kinetics in Cytotoxic T
Lymphocyte-mediated Antiviral Activity
- Highly
Immunodominant
HIV-specific
T Cell Responses against Functional
Constraint Region Are Not Protective Due to Lack of Polyfunctionality
- Rules
Defining
the
Production of HIV Antigenic Peptides
- Novel
Insights
into
HLA Alleles and CD8 T Cell Control
- Loss
of
HIV-1-derived
CTL Epitopes Restricted by Protective HLA-B Alleles
during the HIV-1 Epidemic
- HIV-specific
CD8+
T
Cells Have an Efficient Profile in HLA-B57+ Subjects during
Primary HIV Infection
- Novel
HLA-B*5703-associated
Viral
Gag Polymorphism
- Evolving
Influences
of
Favorable HLA Alleles on Viral Load in Untreated Zambians
with HIV-1C Infection
- The
Expansion
Ability
but Not the Quality of HIV-specific CD8+ T Cells Is
Associated with Protective HLA Class I Alleles in LTNP
- Regulation
of
HIV-specific
CD8<+/> T Cells by Treg Depends on Their HLA
Allele Restrictions
- Detailed
Characterization
of
HIV-1 Evolution under Selective Pressure Mirrors
Progression in HLA-B57+ Subjects
- New
Factors
Associated
with CD8 T Cell Function
- Proliferation
Capacity
and
Cytotoxic Activity Are Mediated by Functionally and
Phenotypically Distinct Virus-specific CD8 T Cells Defined by IL-7Ra
(CD127) and Perforin Expression
- High
Affinity
HIV-1-specific
CTL Become Exhausted in Early HIV-1 Infection
- DNA
Damage
and
p16-mediated Growth Arrest in HIV-1-specific CD8+ T Cells
- HIV-1-specific
CD4+
T
Helper Signals Are Critical for the Maintenance of CD8+ T Cell
Function
- Vaccine-induced
Protection
Is
Associated with Little to No Perforin Expression within
SIV-specific CD8 T Cells
- Prothymosin
alpha
Accounts
for Soluble CD8+ T Cell HIV-1 Transcriptional Inhibition
via Toll-like Receptor 4 Type I IFN Induction
- Exposed
Uninfected
Individuals:
What's New
- HIV-1
Specific
Cellular
Immune Responses in a Population of Persons at Risk
for HIV
- Antigen-stimulated
Th17
Production
and Th17 Gene SNP in HIV-exposed Uninfected Individuals
- New
Discoveries
on
Neutralizing Antibodies
- Autologous
Neutralizing
Antibodies
that Select Viral Escape Variants Emerge Late
after SIV Infection of Rhesus Monkeys
- Sensitivity
to
2G12
Can Be Modulated by Changes within and Proximal to the CD4
Binding Site
- Identification
of
Sera
with Broad and Potent Cross-Neutralizing Activity against HIV-1
in a Group of Patients with Undetectable Viral Loads
- Identification
of
HIV
Neutralizing Antibodies and Their Epitopes from LTNP/EC Patients
by Phage
- New
Information
on
Dendritic Cells and HIV
- Blood
Myeloid
Dendritic
Cells from HIV-1-infected Individuals Display a
Pro-apoptotic Profile that Increases With Disease Progression
- Accelerated
Immuno-senescence
of
Plasmacytoid Dendritic Cells in HIV-infected
Individuals
- Description
of
DCIR
Signalosome Induced after HIV-1 Interaction
- Leukocyte
Immunoglobulin-like
Receptors
Maintain Unique Functional Properties of
Myeloid DC in HIV-1 Controllers
- Soluble
HLA-G
in
HIV-1 Progressors Leads to DC Dysfunction via Binding to ILT-4
- PAMP
Modulate
Maturation
of Dendritic Cells and Modify Their Ability to
Transfer HIV to Resting CD4+ T Lymphocytes
- NK-DC
Cross-talk
Promotes
HIV Persistence in DC: Implication of HMGB1
- Role
of
the
Gut Mucosa in HIV Immunopathogenesis
- HIV
Pathogenesis
Simulates
Immunosenescence and Gut Mucosal Aging
- Chronic
HIV
Leads
to Impairment of DC Function and Signaling Pathways in the
Gut Mucosa
- Differential
Viral
Escape
Kinetics between Plasma and Rectal Mucosa after Acute SIV
Infection in Rhesus Macaques
- CD4
T
Cell
Populations, Including Th17 and Cycling Subsets, Are Intact in
the Gut Mucosa of HIV-1-infected LTNP
- Identification
of
IgA
Phage Mimotopes Recognized by LTNP and HIV-infected Patients
Plasma
- The
Effect
of
HIV-1 and HSV-2 Infection on Dendritic and Lymphocytic
Infiltration in Adult Foreskin Tissue
- Immunodominant
HIV-specific
CD8+
T Cell Responses Are Common to Blood and
Gastrointestinal Mucosa, and Gag-specific Responses Dominate in the
Rectal Mucosa of HIV Controllers
- Mucosal
Damage
in
HIV Infection: Cause or Effect of Higher Activation of
Central Memory CD8+ T Cells in Patients Controlling HIV Replication
Spontaneously?
- Modulating
CD8
T
Cells to Control Virus Replication
- Control
of
Immune
Activation prior to SIV Challenge Is Tightly Linked to the
Protective CD8+ T Cell Immunity Induced by a Live, Attenuated AIDS
Vaccine
- Cyclooxygenase
Type
2
Inhibitor Reduces Progression Markers CD38 and PD-1 and
Selectively Enhances Responses to a T Cell-dependent Vaccine in Chronic
HIV Infection
- Valganciclovir
Reduces
CD8+
T Cell Activation among HIV-infected Patients with
Suboptimal CD4+ T Cell Recovery during ART
- Modulation
of
Vaccine
Responses by RANTES Significantly Lowers Viral Replication
following SIVmac251 Challenge
- IL-28B
Adjuvant
Increases
Granzyme B Content and CD107a Expression in
HIV-specific CD8+ T Cells after DNA Vaccination
- Immune
Modulation
by
41BB Enhances Protection in Non-human Primates following
SIVmac251 Challenge
- MVA-SIV
Boosting
of
AdHu5-SIV Immunized Rhesus Macaques Induces Higher Levels
of SIV-specific CD8+ T Cells but Results in Increased Virus Replication
after SIVmac239 Challenge
- Increased
HIV-specific
Immunity
in HIV-infected Individuals Vaccinated with a DNA
Prime, rAd5 Boost Regimen
- Novel
Approaches
to
Modulate CD4 Cell Infection and Survival
- Dynamics
of
IL-21
Production in the Course of HIV-1 Infection: Consequences for
the Survival of CD4+ T Cells
- Zinc
Finger
Nuclease
Knockout of CCR5 in Stem Cells Controls HIV-1 in vivo
- Prolonged
Control
of
Viremia After Transfer of Autologous CD4 T Cells Genetically
Modified with a Lentiviral Vector Expressing Long Antisense to HIV env
- Quantification
in
vivo
of the Effect of IL-7 on Proliferation, Survival, and
Production of CD4+T Cells: Mathematical Analysis of One Phase I Study
in HIV-1-infected Patients
- Neutralizing
Antibodies:
Induction
and Impact
- Targeting
the
Hydrophobic
Domain of HIV for Inactivation and Vaccine Development
- Oligomeric
Env
gp140
from HIV-1 Pre-seroconversion Strains and Brain as Vaccine
Immunogens for Broad Neutralizing Antibody
- Recombinant
Alphavirus
Replicon
Particles as a Platform to Evaluate Immunogenicity
of Early Transmitted Clade C Virus Envelopes from Primary HIV-1
Infection
- Eliciting
Broadly
Reactive
Neutralizing Antibodies Against HIV-1 gp41
Membrane-Proximal External Region
- Lower
Viral
Loads
in Daily or Intermittent PrEP Breakthroughs are not
Associated with Higher Neutralizing Antibody Titers in Macaques
- New
Approaches
to
Mucosal Vaccination
- Efficacy
of
ALVAC-HIV
and SF2 gp120 Vaccination against SHIV Rectal Challenge in
Macaques
- Intranasal
SIV
DNA/rMVA
Vaccination in Rhesus Macaques Provides Preservation of
Central Memory alpha4b7high+/CD4+ T Cells and Reduces Long-term
Expression of the Immunoactivation Marker CD38
- SIV
DNA/rMVA
Nasal
Vaccination in Female Macaques Provides Better Control
of Viremia and Disease Progression than in Male Macaques
- Mucosae-associated
Epithelial
Chemokine
(CCL28) Modulates Mucosal Immunity in BALB/c Mice
Immunized with HIV-1 Virus-like Particles
- New
Insights
from
Neuroimaging
- Abnormalities
in
High-field
Brain MRI in Primary HIV Infection
- The
Neuradapt
Study:
Clinical, Radiological, and Immunovirological Findings
in Patients with HIV-associated Neurocognitive Disorders
- Impact
of
ApoE
and Cerebrovascular Risk Factors on Brain Structure and
Cognition in HIV in the HAART Era
- HCV/HIV
Co-infection
Affects
Neurocognitive Measures, but Does Not Affect
Neuroimaging Measures
- 2
Patterns
of
Cerebral Metabolite Abnormalities Are Detected on Proton
Magnetic Resonance Spectroscopy in HIV+ Subjects Electively Commencing
ART
- Mechanisms
of
Neuropathogenesis
- NNTC
Gene
Array
Reveals Brain Adaptations and 2 Different Kinds of
HIV-associated Neurocognitive Disorder
- Dysregulated
Glutaminase
in
HIV-1-infected Microglia mediates Neurotoxicity through
the NMDA Receptor
- NMDA
Receptor
Modulation
by the Neuropeptide Apelin: Implications for
HIV-associated Excitotoxic Injury
- Induction
of
the
Unfolded Protein Response Reduces Neurotoxin Production and
Attenuates HIV Replication in Macrophages
- Down-regulation
in
vitro
of Matrix Metalloproteinase-9 in Rat Astrocytes by CCR5
Antagonist Maraviroc: Potential Therapeutical Implication for
HIV-associated Neurologic Disease
- HIV-associated
Dementia:
Pathomechanisms
in Different Stages of the Infection
- HCV
Core
Protein
Induces Neuroinflammation and Potentiates HIV Vpr
Neurotoxicity
-
- Neuropathy
and
Locomotor
Disorder
- A
Multicenter,
Randomized,
Double-blind, Controlled Study of NGX-4010, a
High-concentration Capsaicin Patch, for the Treatment of Painful
HIV-associated Distal Sensory Polyneuropathy
- Mitochondrial
Dysfunction
in
HIV and SIV-associated Sensory Neuropathy
- High
Prevalence
of
Locomotor Disorder in HIV-infected Patients, ANRS CO3
Aquitaine Cohort, 2007 to 2009
- HIV-associated
Neurocognitive
Disorder
Predictors and Co-morbidities in the ART Era
- APOE
e4
and
MBL2 O/O Genotypes Are Associated with Neurocognitive Impairment
in HIV-infected Former Plasma Donors from Anhui Province, China
- CVD
and
CVD
Risk Factors Are Associated with Lower Baseline Neurocognitive
Performance in the SMART Neurology Substudy
- Predicting
HIV-related
Neurocognitive
Dysfunction: The Relevance of Clinical
Factors
- Prevalence
and
Correlates
of Minor Neurocognitive Disorders in Asymptomatic
HIV-infected Outpatients
- HAART-experienced
Subjects
with
HIV-associated Neurocognitive Disorders Have
Longitudinally Persistent Elevated HIV DNA Levels in CD14,+CD16+
Monocytes
- Neurologic
Disease
Burden
in Treated HIV/AIDS Predicts Survival
- Impact
of
Psychiatric
Comorbidities on Clinical Outcomes in HIV-infected
Veterans
- Neurocognitive
Impairment
and
HIV Infection in Nigeria: Functional and Virologic
Correlates
- Utility
of
Diagnostic
Tools for HIV-associated Cognitive Impairment and
Peripheral Neuropathy in Western Kenya: Pilot Testing
- Infection
and
Immune
Activation of CNS Compartments
- HIV-associated
Neurocognitive
Disorder
in Acute and Early HIV Infection
- Neurocognitive
Performance
during
Primary HIV-1 Infection
- Compartmentalization
of
HIV-1
Macrophage-tropism in Brain Tissue of Patients with HIV
Associated Dementia
- Effect
of
Minocycline
on CSF Infection and Intrathecal Immunoactivation in
Untreated HIV-1 Infection: A Pilot Study
- Does
cART
with
Greater CNS Penetration Prevent the Development of CNS
Opportunistic Diseases?
- CSF
Compartmentalization
of
HBV in Chronic HIV-1 Co-infected Patients
- NeuroAIDS
Treatment
Issues
and Controversies
- Higher
CD4
Nadir
Is Associated with Reduced Rates of HIV-associated
Neurocognitive Disorders in the CHARTER Study: Potential Implications
for Early Treatment Initiation
- Correlates
of
Time-to-Loss-of-Viral-Response
in CSF and Plasma in the CHARTER
Cohort
- No
Decrease
in
Intrathecal Immunoactivation during Treatment
Intensification in Patients on Stable ART
- CSF
Escape
Is
Uncommon in HIV-1-infected Patients on Stable ART
- Neuropsychological
Performance
Is
Better in HIV-infected Subjects Treated with Neuroactive
HAART
- cART
Alters
Changes
in Cerebral Function Testing after 48 Weeks in
Treatment-naïve, HIV-1-infected Subjects Commencing cART
- CNS
Toxicity
of
Antiretroviral Drugs
- Molecular
Epidemiology:
Evolution,
Subtype Distribution, and Viral Diversity
- A
Refined
Evolutionary
History for the Emergence of the HIV-1 Subtype C
Epidemic in Africa
- HIV-1
Recombinants
with
Multiple Parental Strains in Low-prevalence, Remote
Regions of Cameroon
- Increase
in
Inter
and Intra Viral Diversity at a Population Level in Uganda from
1994 to 2002
- Genetic
Characterization
of
Diverse HIV-1 Strains Circulating in Russia
- Molecular
Epidemiology
of
SIV in Eastern Chimpanzees and Gorillas
- Identification
of
a
Novel, Highly Divergent HTLV-3 in a Primate Hunter in Cameroon
- HIV
Subtype
D
is Associated with Rapid CD4 Decline in ART-naive Ugandan
Children
- Molecular
Epidemiology:
Dual/Superinfection
and Viral Recombinants
- HIV-2
CRF01_AB:
First
Circulating Recombinant Form of HIV-2
- Evidence
of
HIV-1
Complex and Second Generation Recombinant Strains among
Patients Infected in 1997 to 2007 in France: ANRS PRIMO Cohort
- The
CRF_42BF
Outbreak
in Luxembourg Is Not Related to a Higher Viral
Replication Capacity but to an Elevated Transmission Efficiency
- HIV-1
Superinfection
Surveillance
in an Acute Infection Cohort Using pol
Sequences from Resistance Genotyping: 1996 to 2008
- Inter-clade
Dual
HIV-1
Infection: An Emerging Phenomenon
- Molecular
Epidemiology:
Analysis
of HIV Transmission Patterns
- Analysis
of
the
Degree Distribution of HIV Transmission Networks Inferred from
Viral Sequence Data
- Bayesian
Phylogeography
of
HIV among MSM in the UK Indicates a Few Source Areas
of Widespread Infection
- Combination
of
Phylogenetic
Analysis and Patient Data Provides Valuable Insights in
a Local HIV-1 Epidemic that Can Help the Design of More Targeted
Prevention Programs
- Characterizing
HIV
Transmission
Patterns among Injecting Drug Users following an
Outbreak in Sargodha, Pakistan
- Impact
of
KIR/HLA
on HIV Infection
- Next-generation
Sequencing
for
HLA Typing and MHC Sequence Interrogation for Host
Genetics of HIV Infection
- Effects
of
Killer
Immunoglobulin-like Receptor and Human Leukocyte Antigen
Genes on Heterosexual HIV-1 Transmission
- HLA
Class
II
Allele DRB1*1303 Is Associated with Reduced Viral Loads in 2
Independent Cohorts of Different Ethnicity and HIV Clades of Infection
- NK
Receptor-HLA
Ligand
Requirements for Increased Polyfunctional Potential
in NK Cells from Individuals Carrying KIR3DL1*h/*y+ HLA-B*57
- Host
Genetics
of
HIV Infection: Novel Co-factors, Risk Alleles, and
Biomarkers
- Newly
Identified
MYH9
Risk Alleles Highly Predictive of HIV-associated
Nephropathy
- Genome-wide
Association
Study
to Discover AIDS-restriction Candidate Genes and
Investigate the Role of Polymorphisms in HIV-dependency Factors
- Gene
Expression
Can
Predict the Extent of CD4+ T Cell Recovery in
HIV-infected Individuals during Suppressive ART
- mRNA
Biomarkers
for
Prediction of CD4 Immune Recovery with ART in Persons
with AIDS in Sub-Saharan Africa
- Multi-cohort
Identification
of
a New Chemokine Receptor Risk Allele Involved in AIDS
Long-term Non-progression
- Insights
into
Factors
Affecting Acute HIV Infection
- http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=19&Abs=38960
- Escape
at
KK10
Epitope Fails to Explain Divergent Disease Progression in an
HLA-B*27 Transmission Pair
- Correlation
of
Peak
and Duration of Viremia with Resting CD4+ T Cell Infection in
Acute HIV Infection
- Immunological
and
Virological
Comparison between Long-term ART-treated HIV-1
Seroconverters and Long-term Non-progressors
- Gag-Protease-mediated
Fitness
Is
Associated with Viral Set Point in Individuals Acutely
Infected with HIV-1 Subtype C
- A
Comparison
of
Markers of Immune Activation, Inflammation, and HLA Type
in Primary HIV Infection
- Prevalence
and
Outcome
of Patients Presenting with Thrombopenia at the Time of
Primary HIV Infection: A Study Based on 959 Patients Enrolled in the
ANRS PRIMO Cohort
- Replication
Kinetics
of
Autologous Neutralizing Antibody Escape in Env during Early
Subtype C Infection
- Phenotypic
Characterization
of
HIV-1 Co-receptor Use in Primary Infection in both
Plasma and PBMC Samples
- Non-synonymous
Mixtures
Reveal
Fixation of Viral Population after 3 Years of Infection
- Incidence
of
Major
Clinical Outcomes in a Cohort of Ugandan and Zimbabwean Women
with Primary HIV-1 Infection
- Biomarkers
and
Treatment
during Acute HIV Infection
- Interleukin-6
and
D-dimer
in Primary HIV Infection: Effect of Short Course ART and
Treatment Discontinuation
- A
Comparison
of
HIV Viral Rebound following ART Cessation in Primary and
Chronic HIV Infection
- Impact
of
Early
ART on Proviral HIV-1 DNA and Plasma Viremia in Acutely
Infected Patients
- Strong
Effect
of
Early ART during Primary HIV-1 Infection in Preventing
further Spread of HIV in Sexually Active Men Having Sex with Men
- Molecular
Characterization
of
HIV Transmission and Acute Infection
- A
Significant
Transmission
Bottleneck among Newly and Recently
HIV-1-infected IDU in St Petersburg, Russia
- Molecular
Cloning
and
Biological Characterization of Full-length
Transmitted/Founder Viruses from Injection Drug Users, MSM, and
Heterosexuals
- Ultra-deep
Sequencing
Accurately
Detects HIV Intraclade Dual Infection
- HIV-1
Superinfection
with
a Drug-resistant Strain in a Patient Successfully
Controlled with ART
- Phylogenetic
Linkage
and
Correlate Analysis in HIV-1 Cohorts: A Complete Software
Solution
- HIV
Transmission
and
the Mucosa
- Effect
of
Cervical
Infections on Genital HIV-1 Shedding in Women Receiving ART
- Examining
Paths
for
HIV Entry and Interactions with the Female Genital Epithelium
- Cervical
Immune
Activation
and HIV Shedding in the Female Genital Tract during
HIV-1 Infection
- Phase
of
Menstrual
Cycle Influences Susceptibility to SHIV in a Macaque Model
for HIV-1 Infection
- Correlation
of
Rectal
HIV-1 RNA Shedding with Plasma Viral Load Is Not Affected by
Rectal STIs in MSM with Access to cART
- ART:
New
Agents
and Novel Approaches
- Inhibition
of
HIV-1
Infection by Banana Lectin
- Small
CCR5
Ligand-mediated
Allosteric Inhibition of Gp120 Binding Correlates
with Inverse Agonism at CCR5 but not with Anti-HIV Activity
- RS-788,
a
Prodrug
of B-D-3’-Azido-2,6-diamino-2’,3’-dideoxypurine, Exhibits
Potent Activity against NRTI-resistant HIV-1
- Development
of
Dual-targeted
Antivirals against HIV and Herpesviruses
- Potent
HIV-1
Integrase
Inhibitors Assembled on Nucleobase Scaffolds: Anti-HIV
Activity, SAR Analysis, Microsome Stability, Cytochrome P450 Data, and
Lead Optimization
- Activity
of
QNL111,
an Integrase DNA-binding Inhibitor, on the HIV-1 DNA
Integration Process
- Expression
of
Interfering
RNA from a Chimeric, HIV-1 Tat-inducible RNA Pol II
Promoter
- Peptide-based
Inhibitors
of
HIV-1 Pol-protein Maturation
- Identification
of
HIV-1
Capsid Assembly Inhibitors
- Effect
of
Valproic
Acid to Purge HIV Reservoir: A Multicenter Randomized
Clinical Trial
- Mutations
Based
on
Viral Decay Acceleration in the HIV-1 Genomes of a Clinical
Population Treated with the Mutagenic Nucleoside KP1461
- Epigenetic
Drug
Gar1041
in Combination with ART Significantly Reduces the Proviral
DNA Reservoir in SIVmac251-infected Macaques
- Plasma
HIV
RNA
Monitoring: Suppression and Persistent Viremia
- Predictors
of
Attaining
<1 Plasma HIV/RNA copies/mL in a Large Italian
Cross-sectional Study
- Frequency
of
HIV/RNA
Monitoring: Impact on Outcome of ART
- HIV-infected
Patients
with
Positive MT-2 Cultures May Need More Frequent Monitoring
and/or HAART Initiation at Higher CD4 Counts
- Low
Level
HIV-1
Viremia in Thai Women 24 Weeks after Treatment Initiation
with NNRTI-based ART Was Not Associated with Prior Single-dose
Nevirapine Exposure or Viral Resistance Mutations
- Episodes
of
HIV
Viremia and the Risk of Non-AIDS Events among Successfully
Treated Patients
- Persistent
Low-level
Viremia
Is Associated with Increased Risk of Virologic
Failure and Mortality
- Association
between
Low-level
Viremia below 50 Copies/mL and Risk of Virologic
Rebound in HIV-infected Patients Receiving HAART
- The
Rate
of
Virologic Decay Explains Immunologic Recovery after ART
- Keys
to Successful Outcomes on ART
- Predictors
and Time Trends of Stably Suppressed Viral Load among HIV-1-infected
Individuals on cART in the Swiss HIV Cohort Study
- Relative
Effectiveness of Preferred Initial Antiretroviral Regimens in the CFAR
Network of Integrated Clinical Systems Cohort
- Early
ART Compared to Deferred ART during Acute Opportunistic Infection Leads
to a Reduction in the Systemic Inflammatory Response Resulting in
Improved Immunologic Outcomes
- A
One-pill, Once-daily Fixed-dose Combination of Efavirenz, Emcitrabine,
and Tenofovir Disoproxil Fumarate Regimen Is Associated with Higher
Unannounced Pill Count Adherence than Non-one-pill, Once-daily Regimens
- Elvucitabine
vs Lamivudine with Tenofovir and Efavirenz in ART-naïve
HIV-1-infected Patients: 96-week Final Results
- Effect
in vitro of CCR5 Antagonists on Innate Immune System: Maraviroc
Inhibits the Migration of Neutrophils, Macrophages, and DC
- Effect
of CCL3L1 Copy Number Variation on CD4 Cell Recovery in
Treatment-naïve Patients: 96-week Results from the Maraviroc in
Treatment-naïve Patients Study
- Sustained
Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination
ART in Treatment-naive HIV-1-infected Patients
- Sustained
Antiretroviral Effect of Raltegravir at Week 156 in the BENCHMRK
Studies and Exploratory Analysis of Late Outcomes based on Early
Virologic Responses
- Similar
Immunologic Responses to Modern HAART among IDU and Non-IDU in a
Populational Setting
- First
Line of Defense: ART in Resource-limited Settings
- First-line
ART Outcomes in HIV-infected Adults in Ho Chi Minh City, Vietnam
- A
Comparison of the Immunologic Efficacy of ART in Resource-replete vs
Resource-limited Settings
- Do
Predictors of Late Clinical Progression on First-line ART Differ from
Predictors of Early Clinical Progression?
- Initial
CD4 T Lymphocyte Response Is a Strong Predictor of Death in African
Cohort Despite Full Virologic Suppression on HAART at 6 Months
- The
Effect of Initiating Patients on HAART at CD4 Counts above 200 on
Virologic Failure and Death in South Africa: Evidence from the CIPRA-SA
Trial
- Morbidity
in HIV-1-infected Individuals in Rural Uganda 1990 to 2008
- Rate
of Mortality, Loss to Follow-up, Viral Suppression, Immune Recovery,
and Maintenance of Initial Antiretroviral Regimen at 4 Years: 3045
Chilean Patients
- Failure
to Second-line Therapy and Associated Mortality in 27 MSF-supported
African and Asian ART Programs
- Proportion
of Individuals Likely to Need Treatment for CD4 Thresholds
<200,<350, and <500 cells/µL
- Life
Expectancy
on ART
- Life
Expectancy
of Recently Diagnosed Asymptomatic HIV-infected Patients
Approaches That of Uninfected Individuals
- Time
with
CD4 Cell Count above 500 cells/mm3 Allows HIV-infected Men, but
Not Women, to Reach Similar Mortality Rates to Those of the General
Population: A 7-year Analysis
- Mortality
and
Loss to Follow-up by Socio-behavioral Group in Patients Starting
ART in the Swiss HIV Cohort Study
- Survival
Outcomes
and Effect of Early vs Deferred Combination Antiretroviral
Therapy (cART) among HIV-1-infected Patients Diagnosed at the Time of
an AIDS-defining Event in Europe and Canada: a Collaborative Cohort
Analysis (1997 to 2004)
- Activity
and
Escape from HIV Entry Inhibitors
- Development
of
Resistance to the Natural HIV-1 Entry Virus Inhibitory Peptide
(VIRIP)
- Co-receptor
Tropism
and Viral Resistance Following Short-term Monotherapy with the
Anti-CCR5 Monoclonal Antibody PRO 140
- Relative
Replicative
Fitness of HIV-1 Mutants Resistant to Enfuvirtide
- Maraviroc
Fully
Inhibits Dual-R5 Virus in Dual/Mixed HIV-1 Infected Patients
- HIV-1
Envelope
Determinants and Temporal Analysis of Vicriviroc Resistance in
a Subtype C Clinical Isolate
- Two
Step
Escape Pathway of the HIV-1 Subtype C Primary Isolate Induced by
the in vitro Selection of Maraviroc
- Mechanisms
of
Virologic Failure with Maraviroc in Treatment Naïve HIV-1
Infected Patients through 96 weeks
- Factors
Associated
With HIV-1 Tropism Determined in Proviral DNA in
Antiretroviral-Treated Patients With Fully Suppressed Plasma HIV Viral
Load
- Reanalysis
of
Co-receptor Tropism in HIV-1-infected Adults Using a Phenotypic
Assay with Enhanced Sensitivity
- Genotypic
Analysis
of the HIV-1 gp120 V3 Loop for Treatment Experienced Patients
Enrolled into the MOTIVATE Studies and Who Received Maraviroc +
Optimized Background Therapy
- Prediction
of
HIV Co-receptor Use
- Predicting
HIV-1
Co-receptor Usage and Response to CCR5 Inhibitor Therapy through
Episomal cDNA
- Determining
HIV-1
Coreceptor Tropism Using PBMC Proviral DNA Derived from Aviremic
Blood Samples
- New
V3-genetic
Signatures Modulate Co-receptor Usage in vivo and the
Interaction with CCR5 N-terminus
- A
Highly
Sensitive and Specific Model for Predicting HIV-1 Tropism in
Treatment-Experienced Patients Combining V3 Loop Sequences
Interpretation and Clinical Parameters
- High
Resolution
Tropism Kinetics by Quantitative Deep Sequencing in
HIV-1-infected Subjects Initiating Suppressive First-line ART
- Large-scale
Application
of Deep Sequencing Using 454 Technology to HIV Tropism
Screening
- Resistance
to
Reverse Transcriptase Inhibitors
- Derivatives
of
Mesoxalic Acid Inhibit Translocation of HIV-1 Reverse Transcriptase
- Nucleic
Acid
Template Dependent Risk of PCR-Induced K65R Mutation in Subtype C
HIV-1 Isolates
- Template-Dependent
Mechanisms
Involved in K65R Drug Resistance Development in Subtype B
and C HIV-1
- K65R,
L74V/I,
and M184V Mutations Are Associated with Hypersusceptibility to
First and Next Generation NNRTI
- Differential
Impact
of Amino Acids Arg, Ser, and Thr at HIV-1 Reverse Transcriptase
Position 70 on Susceptibility towards NRTI and Foscarnet
- Mechanism
of
Resistance to GS-9148 Associated with Q151L in HIV-1 Reverse
Transcriptase
- Selection
in
vitro of a Novel Etravirine Associated Resistance Mutation in B and
non-B HIV-1 Subtypes
- Resistance
Associated
Mutations to Etravirine in Antiretroviral-naïve
Patients Infected with Non-B HIV-1 Subtypes
- Resistance
to
Integrase Inhibitors
- Resistance-associated
Mutations
to Integrase Inhibitor S/GSK1349572 in HIV-1 Integrase
Inhibitor-naive and Raltegravir-experienced Patients
- S/GSK1349572
Is
a Potent Next Generation HIV Integrase Inhibitor and Demonstrates a
Superior Resistance Profile Substantiated with 60 Integrase Mutant
Molecular Clones
- Comparison
of
Raltegravir Susceptible and Resistant Viruses Define the
Contribution of Secondary Mutations to Reductions in Raltegravir
Susceptibility
- Short
-Term
Raltegravir Monotherapy Does Not Predispose Patients to Develop
RAL Resistance during Subsequent Combination Therapy: Analysis of
Samples from Protocol 004
- Raltegravir
Genetic
Resistance Patterns in HIV-2 Infected Patients Failing
Raltegravir-containing Regimen
- Resistance
to
Protease and Maturation Inhibitors
- The
Binary
Protease Inhibitor, Darunavir, Has a High Genetic Barrier to the
Emergence of Resistant HIV-1 Variants
- Bayesian
Network
Analysis of Resistance Pathways in HIV-2 Protease
- Identification
of
HIV-1 Matrix Determinants of Protease Inhibitor Susceptibility and
Replication Capacity
- Mutations
in
the HIV Protease Can Enhance the Levels of Bevirimat Resistance
- Detection
of
Minority Resistance Mutations
- Sensitive
Quantification
of Drug-resistant Minor Variants Using a Simplified
Design that Tolerates Viral Sequence Heterogeneity
- Detection
of
Minority K65R Variants in NRTI-naive Subtype B and C HIV-1-infected
Individuals
- Sentinel
Mutations
in Standard Population Sequencing Can Predict the Presence of
RT Major Mutations Detected Only by 454-Pyrosequencing
- Primary
Mutations
Associated with Resistance to Raltegravir are not Detectable
by Pyrosequencing in Integrase-Inhibitors Naive Patients
- Ultradeep
Sequencing
Refines Phenotypic Predictions to Darunavir, Etravirine, and
Other Protease and Reverse Transcriptase Inhibitors in Heavily
Pre-Treated Subjects Infected with Multidrug Resistant HIV-1
- Evaluation
of
Sample Storage Technology
- Effect
of
Storage Conditions on HIV-1 RNA Quantification and Polymerase Chain
Reaction Amplification for Drug Resistance Genotyping from Dried Blood
and Plasma Spots
- HIV-1
Drug
Resistance Genotyping and Subtyping Using Dried Fluid Spots,
United States, 2005 to 2009
- Minority
Resistance
Detection in Stored Dried Blood Spots Indicates High
Specimen Integrity and Provides an Expansive Record of Archived
Resistance
- Evaluation
of
SampleTankers®, a Resource-Limited-Setting-Friendly-Sample
Collection Device for HIV-1 Drug Resistance (DR) Genotyping Analysis
- Genotypic
Assays
for HIV Drug Resistance
- Evaluation
of
an Affordable Assay for Drug-resistance Genotyping of All Major
HIV-1 Subtypes
- HIV-1
Genotypic
Resistance Tests Performed in Cellular DNA are Less
Informative than those Collected from Previous Plasma RNAs in Treatment
Experienced Patients with Suppressed Viremia: a Sub-Study of
EASIER-ANRS 138 Trial
- Improved
Genotypic
Algorithm for Predicting Etravirine Susceptibility:
Comprehensive List of Mutations Identified Through Correlation with
Matched Phenotype
- Simultaneous
Detection
of HIV-1 Drug Resistant Minority Genotypes by a Multiplex
Oligonucleotide Ligation Assay
- Phenotypic
Assays
for HIV Drug Resistance
- Genotypic
Predictions
of CXCR4 Use Are Significantly Impacted by Phenotypic Assay
Sensitivity and Disease Stage
- Assessing
Replication
Capacity and Susceptibility to Maturation and Protease
Inhibitors Using a PhenoSenseHIV Assay that Captures Contiguous gag-pro
Sequences
- Novel
High-throughput
HIV-1 Protease-resistance Phenotypic Assay Using
Cell-free Protein Production System
- Toward
Optimal
ART for HIV-2 Infection: Can Genotypic and Phenotypic Drug
Resistance Testing Help Guide Therapy in HIV-2?
- Prevalence
and
Consequences of Transmitted Drug Resistance
- Prevalence
of
Transmitted Antiretroviral Drug Resistance among Newly-diagnosed
HIV-1-infected Persons, US, 2007
- Prevalence
of
Mutations Associated with Transmitted Drug Resistant HIV among BED
Recent Versus Long-term Infections, US, 2006
- Prevalence
and
Virologic Consequences of Transmitted Drug Resistance Mutations in
Uganda
- Association
with
Transmission of M184V/I and a Reduced Viral Load in
Therapy-naïve Patients in the CFAR Network of Integrated Clinical
Systems Cohort
- Changing
Prevalence
of Multidrug Resistance
- Methods
for
Estimating the Prevalence of Multidrug Resistance in
ART-experienced Patients in North America
- Decreasing
Prevalence
of Drug Resistance Mutations over a 7 Year Period in the
CFAR Network of Integrated Clinical Systems
- Opposite
Trends
in Multiclass HIV-1 Drug Resistance and Exhaustion of Drug
Options in Treatment-experienced Patients Undergoing Resistance Testing
in 7 Western European Countries from 1997 to 2008
- Adherence–Drug
Resistance
Relationships
- Strong
Association
between Medication Possession Ratio and Early Virological
Outcomes in Adults on ART in Côte d’Ivoire
- Adherence-resistance
Relationships
for Lopinavir/ritonavir (LPV/r)-based Regimens in
Treatment-experienced Subjects
- Mechanisms
of
Activity and Failure of ART
- Genotypic
Resistance
at Viral Rebound in Antiretroviral-Naive Subjects Randomized
to Receive Lopinavir/Ritonavir (LPV/r) or Efavirenz (EFV)-Based
Regimens in South Africa - A Substudy of the Phidisa II Trial
- Estimation
of
Virological Residual Activity on a Regimen of
Abacavir/Zidovudine/Lamivudine
- Risk
of
Virological Failure of Antiretroviral Regimens including Nevirapine,
Tenofovir, and Emtricitabine (or Lamivudine) in Previously Treated
HIV-1-infected Patients
- High
Frequency
of Protease Drug Resistance Mutation among HIV-1 Infected
Patients Exposed to Second-line Antiretroviral Regimen in South India
- Bulk
and
Clonal Resistance Analyses in Highly Experienced Patients Failing
Raltegravir, Etravirine, and Darunavir/ritonavir Containing Regimen
(ANRS 139 TRIO Trial)
- Strategies
to
Prevent HIV Drug Resistance
- Early
Switch
Based on Virological Failure Reduces Complexity of HIV-1 Drug
Resistance
- Patient-Selected
Treatment
Partners Did Not Protect against Development of Resistance
during NNRTI-based HAART in a Randomized Clinical Trial
- Predicted
Effect
on Transmission of HIV-1 Resistance of Timing of Implementation
of Viral Load Monitoring to Determine Switches from First to Second
Line Antiretroviral Regimens in Resource-limited Settings
- Pharmacokinetics
and
Pharmacodynamics of Entry Inhibitors
- Achieving
a
Target Exposure to PRO 140 Results in Maximal Viral Load Reduction by
Subcutaneous or Intravenous Administration
- Pharmacokinetics
(PK)
and Pharmacodynamics (PD) of TBR 652, a Chemokine Receptor 5
(CCR5) Antagonist, in HIV 1-Infected, Antiretroviral (ARV)
Treatment-Experienced, CCR5 Antagonist–Naïve Patients
- Solute
Carrier
Organic Anion Transporter 1B1 (SLCO1B1) Mediates Transport of
Maraviroc Using a X. leavis Model
- Pharmacokinetics,
Pharmacodynamics,
and Pharmacogenetics of NRTI and NNRTI
- Association
of
ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the
German Competence Network for HIV/AIDS
- Integrating
Pharmacogenetics
and Population Pharmacokinetic Analysis: Simulating
the Impact of CYP2B6 516G>T for 400 mg Once Daily Nevirapine Dosing
- Nevirapine
Pharmacokinetics
When Initiated at 200 mg or 400 mg Daily in HIV-1 and
Tuberculosis Co-infected Ugandan Adults on Rifampicin
- Nevirapine
Increases
Lumefantrine Exposure in HIV-infected Patients
- Concentrations
of
Efavirenz in Hair Correlate Strongly with 24-hour Intensive
Pharmacokinetic Measurements and with Virologic Outcomes
- Assessment
of
Bioequivalence of Tenofovir, Emtricitabine, and Efavirenz (Atripla)
Fixed-dose Combination Tablet Compared with a Compounded Oral Liquid
Formulation Derived from the Tablet
- Lack
of
Interaction between Etravirine and Raltegravir plus
Darunavir/Ritonavir When Combined in Treatment-experienced Patients: A
Substudy of the ANRS 139 TRIO Trial
- Thymidylate
Synthase
Polymorphisms Determine Stavudine Triphosphate Intracellular
Levels in HIV-1-infected Patients Treated With a Stavudine-based
Antiretroviral Regime
- Antiretroviral
Agent
Penetration into Genital Secretions
- Raltegravir
Concentrations
in the Cervicovaginal Compartment Exceed the Median
Inhibitory Concentration in HIV-1-infected Women Treated with a
Raltegravir-containing Regimen: DIVA 01 Study
- Steady-state
Raltegravir
Penetration in Seminal Plasma of Healthy Volunteers
- Darunavir
Concentrations
in Seminal Plasma in Patients Receiving
Darunavir/ritonavir (DRV/r) Monotherapy: A MONOI-ANRS 136 Substudy
- Darunavir
(DRV)
Concentrations Exceed the Protein-corrected (PC) EC50 for Wild
Type HIV in the Semen of HIV-1 Positive Infected Men
- Maraviroc
Levels
in Cerebrospinal Fluid (CSF) and Seminal Plasma from
HIV-Infected Patients
- Pharmacokinetics
and
Drug Interactions of Integrase Inhibitors
- Raltegravir
is
a Substrate for the Influx Transporters OAT1 and PEPT1 and the
Efflux Transporter Pgp But Is Not Transported by OATP1A2, OATP1B1,
OATP1B3, OCT1, NTCP, or PEPT2
- Intracellular
and
Plasma Pharmacokinetics of Raltegravir in HIV-Infected Patients
- MPC-4326
Drug-Drug
Interaction Profile
- Effect
of
Atazanavir and Atazanavir/Ritonavir on the Pharmacokinetics of the
Next Generation Integrase Inhibitor, S/GSK1349572
- Pharmacokinetics
and
Drug Interactions of Protease Inhibitors
- Identification
of
Novel Factors that Influence Atazanavir Exposure in a Diverse
Population of HIV-infected Women under Conditions of Actual Use
- A
Population
Pharmacokinetic Model Illustrates an Association Between a
Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance
- Immune
Activation
Mediated Change in the Plasma Binding Protein Alpha-1-Acid
Glycoprotein Alters Plasma Lopinavir Concentrations
- Pharmacokinetic
Interactions
Between Buprenorphine/Naloxone and Once-Daily
Lopinavir/Ritonavir
- Bidirectional
Pharmacokinetic
Interaction Between Posaconazole and Fosamprenavir
- Laboratory
Macrophage
Screening Assays Predict Pharmacokinetics of Controlled
Release Nanoformulated Antiretroviral Drugs
- Hepatitis
B:
Epidemiology and Prevention
- A
Randomized
Controlled Trial Comparing the Efficacy and Safety of 4
Intramuscular Double Doses or 4 Intradermal Low Doses with 3
Intramuscular Standard Doses of HBV in HIV-infected Adults: Results of
the ANRS HB03 VIHVAC-B Trial
- Accelerated
Hepatitis
B Vaccination Schedule in HIV-infected Patients
- Hepatitis
B
Vaccine Response Predicts Progression to Clinical AIDS or Death
- Genotype
G
Hepatitis B Virus (HBV) and Advanced Liver Fibrosis in HIV/HBV
Co-infected Patients
- HBV
DNA
Is Not Detected in the Semen of Patients with Chronic Hepatitis B
and Undetectable Serum HBV DNA as a Result of Nucleotide Antiviral
Treatment
- Clinical
and
Laboratory Factors Associated with Isolated Hepatitis B Core
Antibody (anti-HBc) Status Among HIV-infected Subjects in the
Multicenter AIDS Cohort Study (MACS)
- Hepatitis
B
Viruses Infecting Wild African Great Apes
- Hepatitis
B:
Treatment
- Tenofovir
Is
Effective in Suppressing Hepatitis B Viremia in HIV/HBV Co-infection
Regardless of Previous Lamivudine/Emtricitabine Treatment
- 5-Year
Tenofovir
Therapy Is Associated with Maintained HBV Response and Renal
Toxicity in HIV/HBV Co-infected Patients
- A
Longitudinal
Analysis of Factors Associated with HBV DNA Suppression in
an International Prospectively-followed HIV/HBV Co-infected Cohort
- High
Early
Mortality in Chronic Hepatitis B and HIV Co-infected Kenyan
Patients Starting HAART and Emergence of Lamivudine Resistance
- HBeAg
Index
Measurement is Predictive of HBe Seroconversion in HIV-HBV
Co-Infected Patients Treated with Tenofovir (TDF)
- http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=19&Abs=39202
- Mutational
Analysis
of Baseline HBV pol Mutations and Response to Entecavir (ETV)
Intensification in Extensively Tenofovir (TDF) and Lamivudine
(3TC)/Emtricitabine (FTC) Experienced HIV-HBV Co-infected Patients with
Suppressed HIV RNA
- The
Synergistic
Interaction Between Immunological and Pharmacological
Selective Pressure in HIV-HBV Co-infected Patients is a Potent Driver
of HBV Evolution and Drug Resistance Emergence
- Treatment-induced
and
Vaccine Escape HBV Mutants in HIV-HBV Co-infected Patients: A
Longitudinal Analysis
- Acute
Hepatitis
C Infection
- Kinetically
Guided
PEG Alfa-2a and RBV Therapy for HIV-+ Adults with Acute HCV
Infection
- The
Use
of Week 4 HCV-RNA After Acute HCV Infection (AHC) to Predict
Chronic HCV Infection
- Treatment
Outcome
of Acute Hepatitis C Virus Infection in HIV-infected MSM: The
Effect of Treatment Length
- Liver
Fibrosis
Progression after Acute HCV Infection (AHC) in HIV+
Individuals
- Hepatitis
C:
Epidemiology and Outcomes
- Hepatitis
C
Epidemic among HIV+ Men Who Have Sex with Men Started before 2000
- Declining
Hepatitis
C Virus (HCV) Incidence Over 20 Years among HIV Positive and
Negative Injection Drug Users (IDU) in Baltimore, MD (1988 to 2008)
- Incidence,
Genotype
Distribution, and Prognosis of Sexually Transmitted Acute
Hepatitis C in a Cohort of HIV-infected Patients
- Molecular
Epidemiology
of HCV Genotypes Among Injection Drug Users in Taiwan:
Identification of A New Subtype 6v and Unique Recombinant Form_2b6v
- Factors
Associated
with Hepatitis C Viral Load in a Nation-wide French Cohort
of HIV-HCV Co-infected Patients (ANRS C013 HEPAVIH)
- Impact
of
HTLV-1 Simultaneous Infection on the Curse of HIV/HCV Co-infected
Patients
- Factors
Associated
With Liver Disease Severity in a Cohort of Patients with HIV
- All-Cause
Mortality
in HIV-Infected Patients in Spain Compared to the General
Population according to HCV Status
- Hepatitis
C:
Predictors and Determinants of Response to Therapy and Its
Complications
- Quasispecies
Diversity
of the HCV NS3/4A Protease and Treatment Outcome with
Peginterferon plus Ribavirin in HIV/HCV Co-infected Patients
- Polymorphisms
at
the ENT1 Gene Influence the Rate of Rapid Virological Response to
Hepatitis C Therapy in HIV/HCV-Co-infected Patients
- Temporal
Dynamics
of HCV Genotype in Different Compartments May Influence the
Anti-HCV Treatment Response in HIV/HCV-infected Individuals
- Increased
Microbial
Translocation Is Associated with Lack of Early Virological
Response to Pegylated Interferon + Ribavirin Treatment in HIV/HCV
Co-infected Patients with Good Viro-Immunological Response to HAART
- Insulin
Resistance
Is a Major Predictor of Sustained Virological Response to
Peginterferon and Ribavirin in HIV/HCV Co-infected Patients Undergoing
HCV Retreatment
- Interleukin
28
B Genotype Is a Potent Predictor of Response to Therapy with
Pegylated Interferon plus Ribavirin in HIV/HCV Co-infected Patients
- Evaluation
of
the Anti-Hepatitis C Virus Activity and Pharmacokinetics of
ATI-0810, a Novel Inhibitor of Hepatitis C Virus Replication
- Incidence
and
Predictors of Anemia in HCV/HIV Co-infected Subjects Treated with
Pegylated Interferon (PEG) and Ribavirin (RBV) in A5178 (SLAM-C)
- Hepatitis
C
Therapy: ART Interactions
- Fast
Liver
Damage Progression in HIV/HCV-co-infected Patients in Spite of
Effective HAART
- Biomarkers
of
Inflammation and Coagulation and Risk of Non-AIDS Death (NAD) in
HIV/Hepatitis Co-infected Patients in the SMART Study
- Genetic
Variability
of the Hepatitis C Virus NS3 Protease in HIV/HCV
Co-infected Patients Treated with HIV Protease Inhibitors
- Hepatic
Safety
and Efficacy of Raltegravir in Patients Co-infected with HIV and
HBV or HCV
- Effect
of
Accompanying Antiretroviral Drugs on Virologic Response to PEG-IFN
and Ribavirin in HIV/HCV-Co-infected Patients
- Impact
of
Zidovudine on Hematologic Parameters during Treatment with
Peginterferon alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV/HCV
Co-infected Patients Enrolled in a Large Randomized Double-blind Study
- Hepatitis
C:
Metabolic and Vascular Interactions
- Infection
with
HIV and HCV Enhances the Release of Fatty Acid Synthase Into
Circulation: Evidence for a Novel Indicator of Viral Co-infection
- Hepatitis
C
Viral Load Increases in HIV/HCV Co-infected Patients Initiating
Antiretroviral Therapy and Correlates With Increases in vLDL Particle
Apolipoprotein CIII
- Hepatitis
C
Infection Increases Endothelial Dysfunction in HIV/HCV Co-infected
Patients
- HIV
Infection,
Hepatitis C Infection, and the Risk of Stroke in the
Veterans Aging Cohort Study Virtual Cohort (VACS-VC)
- Fluvastatin
as
an Adjuvant to Pegylated-interferon and Ribavirin in HIV/HCV
Co-infected Patients: A Randomized, Open-label Study
- Hepatitis
Immunology
- The
CD14+,
CD16+ Monocytic Reservoir of Replicating HCV is Significantly
Increased in Individuals with HIV/HCV Co-Infection Compared to
Individuals with HCV Infection Without HIV Co-infection
- High
Rate
of Hepatitis C Infection Clearance in HIV-1 Natural Viral
Suppressors
- HCV
Stimulates
HIV Immune Activation in HIV/HCV Co-infected Subjects on
HAART
- Hepatitis
C
Co-infection Sensitizes CD4+ T Cells Towards Fas-induced Apoptosis in
Viremic HIV-Positive Patients
- Strong
HCV
and HIV Immune Responses in Co-infected Subjects Who Experienced
ALT Flare and/or Rebound HCV Viral Load After ART Initiation
- Influence
of
HAART on Hepatitis C Virus Escape from CD8+ T Cell Immune Pressure
- Successful
Hepatitis
C Virus (HCV) Treatment Improves CD4-T Lymphocyte
Reconstitution in HIV/HCV Co-Infected Adults
- Restoration
of
Virus-Specific T-Cell Responses in HIV and/or HCV Infected Patients
by Using IL-10 and TGF-ß Blocking Peptides
- Contrasting
Effects
of IL-15 and PD-1/L1 Blockade on HBV and HIV-specific effector
CD4+ and CD8+ T cell Immunity in HIV Positive Chronic Hepatitis B
Patients
- Predictors
of
Liver Fibrosis
- Usefulness
of
Three Biomarker Indexes as Predictors of Liver Fibrosis Progression
in a Large Cohort of HIV-Infected Patients Followed for 5 Years
- Impact
of
Immunosuppression on Liver Fibrosis Progression in a Large Cohort of
HIV/HCV Co-infected Patients
- HIV
Mono-infection
Is Associated with a Non-invasive Index of Liver
Fibrosis in Women
- Elevated
Levels
of Serum Markers of Liver Inflammation and Fibrosis in
HIV-Infected Patients Are Associated With Hepatitis C Virus
Co-infection but Not With HAART Use
- Interruption
of
Antiretroviral Therapy (ART) is Associated with Progression of Liver
Fibrosis in HIV/HCV Co-infected Adults
- Hepatitis:
Cirrhosis,
Cancer, and Transplant
- Survival
of
HIV-Infected Patients with Compensated Liver Cirrhosis
- Screening
for
Hepatocellular Carcinoma in HIV/HCV Co-infected Patients: Impact on
Staging, Therapy, and Survival
- In
the
HAART Era, in Viral Cirrhosis Liver Transplant Candidates, HIV
Co-infection Remains as an Independent Predictor of Mortality on the
Waiting List, but Not after Liver Transplantation
- Short-term
Plasma
HIV-1 RNA Viral Load and Immunological Changes Following
Transitory Discontinuation of HAARTafter Liver Transplantation (OLT) in
HIV-1 Infected Recipients
- Outcomes
in
HIV/HCV Hemophilic vs Non-hemophilic Transplant Candidates
- Hepatitis
B
and C: The Next Chapter in the Management of HIV in Resource-limited
Countries
- High
Prevalence
of Unexplained Liver Fibrosis Associated with HIV in Rural
Southwestern Uganda
- Response
to
Antiretroviral Therapy (ART) in Hepatitis B and HIV Co-infected West
Africans
- Factors
Associated
with Hepatotoxicity in an International HIV/HBV Co-infected
Cohort on Long-term HAART
- Characterization
of
Hepatitis B Virus (HBV) and its Association with HIV in an
Antiretroviral Therapy(ART)-naïve, Multi-national Cohort from 2
Randomized Controlled Trials (RCT) of the AIDS Clinical Trials Group
(ACTG)
- Prevalence
of
Hepatitis C Virus Infection among Human Immunodeficiency Virus
Type-1 Infected Pregnant Women in Malawi: The BAN Study
- Prevalence
of
Hepatitis B and C Co-infection and Response to Antiretroviral
Therapy among HIV-infected Patients in an Urban Setting in Tanzania
- Prevalence
and
Clinical Course of Occult Hepatitis B (HBV) Infection in Serology
Negative HIV Patients in Johannesburg, South Africa (SA)
- HBV
Polymerase
and Surface Mutations in a Cohort of HIV/HBV Co-infected
Patients Accessing Lamivudine-based HAART in Kumasi, Ghana
- Hepatitis
E
and GBV-C
- Hepatitis
E
Virus Sero-prevalence and Chronic Infection in HIV Patients with
Unexplained ALT Elevation: The Swiss HIV Cohort Study
- GBV-C
Specific
Antibodies in HIV+ Patients Anti-E2 Antibodies Alone Are Not
Sufficient to Determine an Eliminated GBV-C Infection
- Cardiovascular
Disease:
Pathogenesis
- Ritonavir
and
Lopinavir Boosted with Ritonavir Induce Endothelial dysfunction and
Premature Senescence in Cultured Human Coronary Artery Endothelial
Cells
- Myocardial
Viral
Load Associated with Diastolic Dysfunction in SIV-infected
Macaques
- Increased
Endothelial
Precursor Cells Are Not Associated with Carotid
Intima-Media Thickness Progression in Chronically HIV-1-Infected
Subjects
- Predictors
of
Cardiovascular Risk and Carotid Intima-media Thickness
- Correlation
of
Inflammatory Biomarkers with the Framingham Coronary Risk Score in
Antiretroviral-Naive HIV-1 Infected Subjects
- Visceral
Fat
but Not General Adiposity Is a Predictor of Cardiovascular Disease
in HIV-infected Males
- Improved
Correlation
of Coronary Atherosclerosis with Estimated Glomerular
Filtration Rate Assessed With Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) Equation Than with MDRD and Cockcroft-Gault in
HIV Infected Patients
- An
Individual-Patient
Meta-analysis to Study the Association between
Anti-Retrovirals and Atherosclerosis
- Day-night
Blood
Pressure Changes in Treatment-Naive HIV-Infected Patients
- Progression
of
Atherosclerosis: Role of Inflammation and T Cell Activation
- Earlier
Initiation
of Antiretroviral Therapy in HIV-Infected Individuals is
Associated with Reduced Arterial Stiffness
- Inflammation
is
Associated with Endothelial Dysfunction among Individuals with
Treated and Suppressed HIV Infection
- T
Cell
Senescence and T Cell Activation Predict Carotid Atherosclerosis
in HIV-infected Women
- Rates
and
Determinants of Progression of Carotid Artery Intima-media
Thickness and Coronary Artery Calcium in HIV Infection
- Cardiovascular
Events:
Assessment, Predictors, and Outcomes
- Evaluation
of
Antiretroviral Agents and Cardiovascular Risk Factors Using Tc99
Testing Stress Testing Outcomes
- N-Terminal-proB-type
Natriuretic
Peptide (NT-proBNP) Predicts Cardiovascular Disease Events
in HIV-Infected Patients: Results of the SMART Study
- Elevated
D-dimer
but Not CRP Levels in HIV+ Patients Prior to Incident
Myocardial Infarction or Other Cardiovascular Disease Event
- Incomplete
Immune
Recovery on HAART Is Associated with Significant More
Cardiovascular Events and a Trend Towards More Non-AIDS Related
Malignancies in Dutch ATHENA Cohort
- The
Impact
of HIV Infection on Outcomes Following Coronary
Revascularization
- Abacavir
and
Cardiovascular Disease: Search for a Mechanism
- Abacavir
Induces
Human Leukocyte Endothelial Cell Interactions
- Abacavir,
a
Competitive Inhibitor of Soluble Guanylyl Cyclase, Increases Platelet
Reactivity
- Changes
in
Cardiovascular Biomarkers with Abacavir: a Randomized, 96-Week Trial
- Dyslipidemia
and
Fat Changes: ART Effects
- Greater
Postprandial
LDL-cholesterol Excursions With Low Dose Ritonavir Vs
Raltegravir in HIV-uninfected Adults: a Randomized Study
- Metabolic
Profiles
and Body Composition Changes in Treatment-Naive HIV-Infected
Patients Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600
mg Each bedtime Combination Therapy: 96-Week Follow-Up
- Fat
Tissue
Distribution Changes in HIV-infected Patients with Viral
Suppression Treated with Darunavir/ritonavir (DRV/r) Monotherapy Versus
2 NRTI + DRV/r in the MONOI –ANRS 136 Randomized Trial : Results at 48
Weeks
- Fat:
Pathogenesis,
Measurement, and Interventions
- Telmisartan
Reverses
Ritonavir Induced Anti-adipogenic Toxicity In An in vitro
Murine Adipocyte Model
- A
48-week
Randomized Study of Uridine Supplementation vs Switch to TDF on
Limb Fat, Mitochondrial Function, Inflammation, and Bone Mineral
Density in HIV Lipoatrophy
- Validation
of
Anthropometry and BIA against DEXA for Body Composition Assessment
in Antiretroviral-naïve HIV-infected Thai Patients
- Complications
of
HIV Disease: Epidemiology and Predictors of Mortality
- Inflammation
and
Mortality in HIV-infected Adults: Analysis of the FRAM Study Cohort
- Non-AIDS
Defining
Events among HAART-Treated Adults in an Urban US vs an Urban
sSub-Saharan African Setting
- Prevalence
of
Poly-pathology is More Common in HIV Infected Patients Than in HIV
Negative Controls in Any Age Strata
- Chronic
Lung
Disease in Adolescents with Vertically-Acquired HIV Infection in
Harare, Zimbabwe
- Complications:
Role
of Genetic Markers and Mitochondrial DNA
- Accumulated
Molecular
Damage and Long-Term Anti-Retroviral Therapy
- Peripheral
Blood
Mononuclear Cell Mitochondrial DNA (mtDNA) and Mitochondrial RNA
(mtRNA) Does Not Predict Lactic Acidosis or Symptomatic Hyperlactatemia
for HIV-infected patients on Antiretroviral Therapy : a Sub-study of
the INITIO Trial
- Hemochromatosis
Gene
Variants and Mitochondrial DNA Copy Number in Chronically Treated,
HIV-infected Persons
- Contribution
of
Genome-Wide Significant Single Nucleotide Polymorphisms to New-Onset
Diabetes Mellitus in HIV-infected Subjects Receiving Antiretroviral
Therapy
- Renal
Disease:
Mechanisms and Outcomes
- Factors
Associated
With Decreased Glomerular Filtration Rate (GFR) in
HIV-infected Adults Enrolled in the MTCT-Plus Initiative in Seven
Sub-Saharan African Countries
- http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=19&Abs=36865
- HAART
is
Associated with Improved Kidney Function in Patients with Impaired
Kidney Function at Baseline but Was Associated with Slight Worsening of
Kidney Function in Patients with Normal Baseline Kidney Function
- Intrarenal
Inflammation
Contributes to HIV-Related Proteinuria
- The
Value
of Urine Protein/Creatinine and Albumin/Creatinine Ratios in
Assessing Renal Disease in HIV Infection
- Renal
Disease:
Incidence Outcomes and Mechanisms of Disease
- Determinants
of
Incident Chronic Kidney Disease in a Cohort of HIV-Infected Patients
with Free Access to Care
- Outcome
and
Prognostic Factors in HIV-1-Infected Dialysis Patients in Spain in
the HAART Era: a Case-Control GESIDA/SEN Study
- Predictors
for
Change in Estimated Glomerular Filtration Rate in HIV-infected
Individuals With or Without cART: The Swiss HIV Cohort Study
- Chronic
Renal
Failure in HIV-Infected Patients: Incidence and Risk Factors
(ANRS CO3 Aquitaine Cohort, France)
- Genetic
Variants
Of ABCC10 Are Associated With Kidney Tubular Dysfunction In
Patients Treated With Tenofovir-containing Regimens
- Efficient
Lymphocyte-to-Epithelial
Cell HIV Transfer Induces Viral Gene
Expression in Renal Tubular Epithelial Cells
- HIV-1
Viral
Protein R Induces ERK and Caspase-8 Dependent Apoptosis in Renal
Tubular Epithelial Cells
- Bone
Disease:
Risk Factors
- High
Prevalence
of Reduced Bone Mineral Density (BMD) in Primary
HIV-infected Men
- Longitudinal
Analysis
of Bone Mineral Density in Aging Men With or at Risk for HIV
Infection
- Changes
in
Bone Mineral Density: 2-year Follow-up of the ANRS CO3 Aquitaine
Cohort
- Bone
Turnover,
and In Particular Osteoclast Activity, is Increased in
Patients with Confirmed Proximal Renal Tubulopathy Within the Swiss HIV
Cohort Study
- Renal
Phosphate
Wasting and Increased Bone Turnover in Tenofovir-Treated
Patients are not Mediated by Low 25(OH) Vitamin D or
Hyperparathyroidism
- Got
Milk?
Vitamin D Deficiency Prevalence and Associations
- Assessment
of
Vitamin D Levels among HIV-infected Persons in the Study to
Understand the Natural History of HIV/AIDS in the Era of Effective
Therapy (SUN Study)
- Prevalence
of
Hypovitaminosis D among HIV+ Patients Enrolled in a Large Italian
Cohort
- High
Prevalence
of Severe Vitamin D Deficiency in cART Naïve and
Successfully Treated Swiss HIV Patients
- Vitamin
D
and HIV-related Complications and HIV Disease Progression in Women in
Tanzania
- Vitamin
D
Deficiency and Bacterial Vaginosis among HIV-infected and -uninfected
Women in the United States
- Immune
Responses
to KSHV/HHV-8
- NK
Cells
Exhibit Distinct Phenotypes in HIV-1 Infection Compared to HIV-1/
HHV-8 Co-infection
- Identification
of
an Immunodominant Late-lytic Kaposi’s Sarcoma-associated Herpesvirus
(KSHV) Specific Epitope; T Cell Memory Phenotypes in KSHV Infections
- Risk
Factors
and Outcomes for AIDS-related Malignancies
- Do
People
with AIDS Develop Cancer at Younger Ages than the General
Population?
- Trends
in
Cumulative Incidence of Cancer Among HIV-infected Patients in North
America
- Functional
Immune
Response is Associated with Risk of Cancer in a Cohort of
HIV-Infected Patients
- Biomarkers
of
Angiogenesis and gHerpeseviruses and the Development of Cancer in
Patients on Episodic and Continuous Antiretroviral Therapy in SMART
- Increased
All-Cause
and Cancer Mortality Associated with HTLV-II Infection
- Cause
or
Consequence? Peripheral CD4 Cell Counts and Hodgkin’s Disease in
Patients on cART
- Short
and
Long Term Effect of Kaposi Sarcoma on the Response to HAART in the
Setting of the South African HIV Epidemic
- Cervical
and
Anal Cancer: Screening, Prevalence, and Therapy
- The
Risk
of HPV-related Cancers Compared to Other AIDS-defining
Malignancies in US Veterans
- Prevalence
and
Persistence of Integrated Oncogenic HPV in HIV+ Women
- High
Levels
of Severe Dysplasia Detected in Anal Biopsies from HIV-infected
Men Who Have Sex with Men in Sydney, Australia
- The
Effect
of HAART on the Incidence of Squamous Cell Cancer of the Anus
- Topical
5-Fluorouracil-Treatment
of Anal Intraepithelial Neoplasia in HIV+ Men:
Results from a Prospective Multicenter Study
- Comparison
of
Conventional Pap Smear and Visual Inspection with Acetic Acid in
HIV-infected Women in Western Kenya
- Diagnostics:
TB
and Pneumocystis jirovecii Pneumonia
- Improved
Immuno-diagnosis
of M. tuberculosis Infection in HIV-infected Patients
Using Monocyte-derived Interferon Gamma Inducible Protein 10 as a New
Biomarker
- Performance
of
Microscopic Observation Drug Susceptibility Assay for the Diagnosis
of TB in Resource-limited Settings
- Real
Time
PCR as a Diagnostic Tool can Improve the Diagnosis of Symptomatic
Pneumocystis Pneumonia in Bronchioalveolar Lavage Fluids
- TB
Screening:
Strategies and Diagnostic Testing
- Intensified
Case
Finding for Active Tuberculosis among Adults Enrolled in HIV Care
and Treatment at an Urban Hospital in Mozambique
- Screening
for
Active Tuberculosis Before INH Chemoprophylaxis in West African
Adults with High CD4 Counts: Inclusion Phase of Temprano ANRS 12136
- The
Effect
of Antiretroviral Therapy on Tuberculosis Sputum Smear Status in
HIV-Infected Individuals in South Africa
- Development
of
a Novel MIG/IP-10 qPCR Assay for Sensitive Detection of
Antigen-specific T Cells and Its Use in the Identification of Latent
Mycobacterium tuberculosis Infection in a HIV/MTB Co-infected
Population
- TB
Incidence:
Impact of ART
- Increased
Baseline
CD4 Cell Count at ART Initiation Decreases Early Mortality and
Incidence of Tuberculosis in an Urban HIV Clinic in Sub-Saharan Africa
- Tuberculosis
Risk
Before and After Highly Active Antiretroviral Therapy Initiation
in a Cohort of HIV-infected Persons in Care
- Changing
Burden
of HIV Infection on Tuberculosis Epidemic in the Metropolitan
Area of Milan
- Incident
Tuberculosis
and Mortality in the Themba Lethu Clinical Cohort,
Johannesburg, South Africa
- Injection
Drug
Users at High Risk for Incident M. tuberculosis Infection in
Tijuana, Mexico
- TB
Outcomes:
HIV, ART, and Immune Mechanisms
- Effect
of
HIV Infection on Outcomes of Therapy for Pulmonary Tuberculosis
Disease in 2 Clinical Trials
- The
Association
of Tuberculosis (TB) Treatment Duration and Intermittency
with Death and TB Recurrence Risk in HIV-Infected Persons
- Immunologic
Benefits
Associated with Suppression of HIV Replication during
Treatment for HIV/TB Co-infection
- Functional
Responses
of Mycobacterial-specific CD4+ T Cells Are Maintained in
Individuals Co-infected with HIV and Tuberculosis
- Multiple
Cytokines
Induced by a New Effective Booster Vaccine against
HIV-associated Tuberculosis
- Multidrug-resistant TB
- Long Term Treatment Outcomes of Patients with Extensively Drug Resistant Tuberculosis (XDR-TB) and HIV
- Impact of HIV Co-infection on Outpatient Multi-drug Resistant Tuberculosis Epidemic in a High-income Metropolitan Setting
- OI Prophylaxis
- May Pneumocystis Prophylaxis Be Safely Discontinued in Virologically Suppressed Patients with CD4 Counts below 200 Cells/µL? The Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
- The Effects of Cotrimoxazole Preventive Therapy & Viremia on Mortality During ART in a South African Program
- IRIS: Incidence and Pathogenesis
- Immune Inflammatory Reconstitution Syndrome (IRIS) among US Subjects Starting Antiretroviral Therapy (ART) in AIDS Clinical Trials Group (ACTG) Study A5202
- TB-Associated Immune Restoration Syndrome is Associated with the Expansion of a Polyclonal and Polyspecific Immune Response Against the Present Pathogen. The ANRS EP21 PARADOX-TB Assay
- T Cell Responses to HIV-1 and Opportunistic Pathogens in HIV-1+ IRIS vs Non-IRIS Patients
- Malaria and HIV
- Plasmodium falciparum Enhancement of HIV-1 Replication in an in vitro Model System
- Elucidating Immune Mechanisms of Disease Exacerbation in HIV/Malaria Co-infection Using a Nonhuman Primate Model
- High Prevalence of “Occult” Plasmodium Infections in HIV-Infected Sub-Saharan Africans Recently Immigrated to Spain
- Clostridium difficile, Leprosy, Leishmania, and Cryptococcal Disease
- Incidence and Risk Factors for Clostridium difficile Infection in HIV Patients from 2003 to 2007
- Effector NKT Cells in Leprosy and HIV Infection
- High Levels of T Lymphocyte Activation and Inflammatory Cytokines Are Observed in Leishmania-HIV-1 Co-infected Individuals
- Trends in Treatment of Adults with Incident Cryptococcosis, South Africa, 2005 to 2008
- Swine Flu Meets HIV
- New Swine Origin Influenza A (H1N1)v in HIV-Infected Patients During the 2009 Outbreak in Mexico City
- LB 2009 H1N1 Virus Infection in HIV+ Adults
- LB Clinical Features of Subjects Infected with HIV and H1N1 Influenza Virus
- LB Immunogenicity of One Dose of Influenza A H1N1v 2009 Vaccine Formulated with and without AS03A-Adjuvant in HIV+ Adults: Preliminary Report of the ANRS 151 Randomized HIFLUVAC Trial
- LB Low Rate of Immunoresponse to the Novel Split Virion, Inactivated, Adjuvanted Pandemic H1N1 Influenza Vaccine in HIV-1-infected Patients
- LB Poor Immunogenicity of the H1N1 2009 Vaccine in Well Controlled HIV-infected Individuals: Interim Results of an Immunogenicity Trial
- LB Elevated 2009 H1N1 Antibody Titers in HIV-infected and Uninfected Women in the US: A Sero-study, March 1 to September 30, 2009
- LB Safety of an Inactivated H1N1 2009 H1N1 Vaccine in HIV-1-infected Pregnant Women, IMPAACT P1086
- LB 2009 H1N1 Immunization in HIV-1 Perinatally Infected Children and Youth
- Influenza: Incidence and Prevention
- Prevalence and Predictors of Seasonal Influenza Vaccination among HIV-Infected Persons Receiving Care in the United States, 2007
- The Cost Effectiveness of Influenza Vaccination among HIV+ Patients Receiving ART
- A Controlled Trial to Compare the Immunogenicity and Efficacy of Three Seasonal Influenza Vaccine Dosing Strategies in HIV Infected Adults
- Pneumococcal Vaccine Responses
- The Impact of Highly Active Antiretroviral Therapy on Antibody Responses Following Pneumococcal Conjugate Vaccination With or Without a TLR9-agonist
- A Randomized Clinical Trial Comparing Revaccination with Pneumococcal Polysaccharide Vaccine (PPV) to Pneumococcal Conjugate Vaccine (PCV) among HIV-Infected Adults
- Response to ART in Resource-limited Countries
- Prognosis of HIV-1 Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: a Collaborative Analysis of Scale-up Programs
- Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a Cohort Study in Busia, Kenya
- Response to Antiretroviral Therapy (ART) of HIV/HCV Co-infected Patients at Outpatient Clinics in Vietnam
- Survival in Care and CD4 Cell Count Gain on First-line ART Depend on Prior CD4 Cell Count and Time on Treatment: Evidence from a Large South African Cohort
- Association Between Early Immune Recovery and Subsequent Mortality Among Malnourished Patients Starting Antiretroviral Therapy in Lusaka, Zambia
- Novel Structured Teaching of HIV Patients in Resource-limiting Setting: Effect of Learning Outcomes on Adherence to Highly Active Antiretroviral Therapy and Immunological Recovery
- The Importance of Clinic Attendance in the First Six Months on Antiretroviral Treatment (ART): Missing Medical Visits Increases Mortality
- Association between Missed Early Visits and Survival among Patients of China National Free Antiretroviral Treatment Cohort
- The Net Cost of Incorporating Resistance Testing into HIV Treatment in South Africa
- Is Tenofovir (TDF) Affordable in Developing Countries? A South African Perspective of the Economic and Budgetary Impacts
- Treatment and Retention in Resource-limited Countries
- Missed Opportunities for HIV Testing and Late Diagnosis Among HIV Infected Patients in Uganda
- A Lost Opportunity: Most VCT Patients Who Test Positive for HIV in a Large South African Clinic do not Initiate HIV Care
- Adult Antiretroviral Therapy in Resource Limited Settings: A Aystematic Review of First-line Treatment Failure and Attrition Rates
- Scale-up of and Retention in PEPFAR-supported HIV ART among Government, Non-Government and Private Clinics, South Africa, 2005 to 2009
- Frequent Regimen Switches Due to Inconsistent Drug Supply among HIV-infected Patients Starting ART in a Rural Ugandan University-based Clinic
- What Happens to Patients Lost to Follow-up from ART Programs?: Evidence from the Themba Lethu Clinic, South Africa
- Cash Transfers to Cover Clinic Transportation Costs Improve Retention in Care in a HIV Treatment Program in Rural Uganda
- Impact of Antiretroviral Therapy Programme Size on Loss to Follow-up: Analysis of the IEDEA-SA Collaboration
- How Do Different Approaches to Estimating Loss-To-Follow-Up Impact on Patient Outcomes on Antiretroviral Therapy? – A Case-Study from the IeDEA-SA Collaboration
- An Empirical Approach to Defining Loss to Follow-Up among Patients Enrolled in Antiretroviral Treatment Programs
- Malnutrition and Nutritional Supplementation: Outcomes
- Oral Candidiasis and Malnutrition in HIV+ Patients prior to HAART Initiation in a South African Urban Cohort
- Nutritional Status Change from Baseline after 3 Months of ARV Therapy is Strongly Associated with Mortality among HIV Patients in Tanzania
- Food Insecurity, Competing Demands, and Health Care Utilization among HIV-Infected Persons Accessing Antiretroviral Therapy (ART) in Rural Uganda
- A High-energy, Micronutrient-fortified Supplement Is Effective for Reducing Nutritional Depletion among HIV-infected, Breastfeeding Women: The Breastfeeding, Antiretrovirals, and Nutrition Study
- Interface of HIV, Nutritional Supplementation, and Breastfeeding: Findings from a Perinatal HIV Prevention Trial in Kampala, Uganda
- Survival of HIV-infected Children in Africa
- Survival of Children HIV-infected Perinatally or Through Breastfeeding: a Pooled Analysis of Individual Data from Sub-Saharan Africa
- Morbidity and Mortality among Infants Born to HIV-infected Women in South Africa: Iimplications for Child Health in Resource-limited Settings
- Response to First-line ART in Children
- Validation of Utility of the WHO (2006) Clinical Criteria for ‘Presumptive Diagnosis’ of Severe HIV Disease in Infants and Children Under 18 Months Requiring ART in Situations Where Virologic Testing is not Available
- Virological and Immunological Responses in Infants Receiving a Lopinavir/Ritonavir (LPV/r)-based Regimen
- Impact of TB Co-infection on Viral Suppression Rates in HIV-infected Children
- Immune Reconstitution Inflammatory Syndrome Related Mortality in HIV-infected Children Admitted After Initiating ART in Uganda
- Outpatient Nutritional Recovery in HIV-Infected Children with Acute Malnutrition in the Era of HAART
- Persistence of Stunting After Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children in South India
- Growth Response to ART in HIV-infected Children From Lilongwe, Malawi
- HIV Drug Resistance after Treatment Failure in Children
- Incidence of Early Virological Failure and the Evolution of Antiretroviral Drug (ARV) Resistance Mutations in Ugandan Children
- Antiretroviral Drug Resistance Mutations in HIV-1-infected Ugandan Children Perinatally Exposed to Single-dose Nevirapine following Virologic Failure to an NNRTI-based Regimen
- The Prevelence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK
- Screening for HIV and TB Co-infection in Adolescents
- Use of Time-Location Sampling for HIV Surveillance in Street Youth
- Burden of Vertically-Acquired HIV Infection and Acceptability of Provider-Initiated HIV Counselling and Testing in a Country with an Early and Severe HIV Epidemic
- High Prevalence of TB and HIV Infection in Adolescents in a South African Community
- HIV-related Complications and Co-infections in Children
- Hospitalization Rates, Reasons, and Risks Among HIV-infected and HIV-uninfected Infants in Pune, India
- Causes of Hospitalization ifor HIV+ Children: Comparison of the Pre-PCP Prophylaxis, Pre-ART, and ART Era
- Prevalence of Hepatitis Coinfection among HIV-Infected Nigerian Children in the Harvard PEPFAR ART Program
- Efficacy of Trimethoprim-Sulfamethoxazole Prophylaxis against Malaria in HIV-Exposed Uninfected Children until 2 Years of Age: A Randomized Clinical Trial
- Trends in incidence of AIDS-defining and Non-AIDS-defining cancer among HIV-infected children in the United States, 1984 to 2006
- Neurodevelopmental Outcomes in Children
- Association Between HIV Infection, ARV Use and Neurodevelopmental Outcomes among Children Aged 0 to 14 Years In Rural Uganda
- The Long-term Impact of HIV Disease Severity on Cognitive and Adaptive Functioning During Childhood and Adolescence
- Association of Vascular Biomarkers with Neurodevelopmental Outcomes in Children with Perinatally Acquired HIV Infection
- Metabolic Complications and Toxicities in Children
- Heightened Inflammation is Linked to Carotid Intima-Media Thickness (cIMT) and Endothelial Activation in HIV-Infected Children
- High Rate of Coronary Artery Abnormalities in Adolescents and Young Adults Infected with HIV Early in Life
- 2-Year Evolution of Triglycerides and Cholesterol in Thai HIV-1-infected Children Receiving First-line NVP or Efavirenz EFV-based Regimen
- Insulin Resistance and Other Metabolic Abnormalities in a Cohort of HIV-1 Vertically Infected Latin American Children: The NISDI PLACES Protocol
- Effect of Lopinavir/Ritonavir on Lipids in HIV-infected Children
- Differences in Body Fat Distribution in HIV-infected vs HIV-uninfected Children
- Lipodystrophy among Children on HAART at the Pediatric Infectious Diseases Clinic, Mulago Hospital
- Renal Safety of Highly Active Antiretroviral Therapy including Tenofovir in Vertically HIV-Infected Youths: a 60-Months Longitudinal Study
- Safety of HAART including Tenofovir on Bone Health in Vertically HIV-infected Youths: A 60-Month Longitudinal Study
- ART Pharmacokinetics, Safety, and Efficacy in Children
- A Pharmacokinetic Comparison of Adult and Pediatric Formulations of RAL in Healthy Adults
- Pharmacokinetic (PK), Safety, and Efficacy Data on Cohort IIA; Youth Aged 6 to 11 Years from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth
- Pharmacokinetics and Safety of Once-Daily Elvitegravir in HIV-infected Adolescents
- A Pharmacokinetic Study of Ritonavir-Boosted Saquinavir in HIV-Infected Children 4 Months to <6 Years Old
- Long-term (>180 weeks) Efficacy and Safety of Fosamprenavir in HIV-Infected Pediatric Patients in Clinical Practice
- Pharmacokinetics of Lopinavir/Ritonavir Crushed vs Whole Tablets in Children
- Pharmacokinetics of Efavirenz Dosed According to the WHO Weight-bands in Children in Uganda
- Safety and Efficacy of NRTI-only Antiretroviral Regimens (NOAR) in HIV-infected Children
- Response to Protective Vaccines in Children
- Persistence of Protective Antibody to Hepatitis B, Japanese Encephalitis, Measles, Mumps, and Rubella up to 3 years After Revaccination in HIV-infected Children with Immune Recovery a
- 28- and 72-week Immunogenicity of One Dose vs Two Doses of Quadrivalent Meningococcal Conjugate Vaccine in HIV-infected Youth
- Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children
- Immune Response to Perinatal HIV Infection
- http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=19&Abs=37618
- Decreased Dendritic Cell Function and Altered Immune Activation in HIV+Pediatric Patients in Chennai, India- A Prospective Study
- Immunological Factors Associated With Long-Term Non-Progressive HIV-1 Infection in Childhood
- Impact of ART on Disease Pathogenesis in Children
- CD4 T Cell Depletion, and Not Age, May Be a Driver of Abnormal CD4 Cell Compartments in HIV-infected Children Initiating ART in Uganda
- Antiretroviral Treatment Within 12 Weeks of Age Is Associated with Induction of IL-7 Production, Boosted Naïve T cell Frequency and Lower Immune Activation
- HIV-1 Viremia or Delayed ART Initiation Associate with Increased LPS Plasma Levels in Perinatally Infected Infants
- Associations of Pro-inflammatory Cytokine Levels with Lipid Profiles, Growth, and Body Composition in HIV-infected Children Initiating or Changing Antiretroviral Therapy
- Immunologic and Viral Dynamics Among HIV-infected Children After Planned Treatment Interruption: a Substudy of the Pediatric European Network for Treatment of AIDS (PENTA) 11 Trial
- Diagnostics for HIV Infection in Exposed Infants
- A Point-of-Care DNA PCR Test for Infants
- Evaluation of a Carbon Nanoparticle-based Rapid p24 Assay for the Diagnosis of HIV in Infants: Results from Cape Town
- Factors Influencing PMTCT Implementation
- Missed Opportunities in Uptake of PMTCT of HIV Interventions; Are Health Systems Failing HIV-infected Mothers?
- Non-disclosure of Maternal HIV Status to the Father during Pregnancy: Risk Factors and Consequences
- Antiretroviral Regimens, Viral Response, and MTCT Outcomes
- Pregnancy Outcomes in HIV-infected Women Using Non-Zidovudine HAART in Europe: 2000 to 2009
- When Should HAART Be Initiated in Pregnancy to Achieve an Undetectable Viral Load?
- Factors Associated with Viral Load Control and Its Impact on HIV Vertical Trasmission Rates in HIV+ Pregnant Women from Rio De Janeiro during the HAART Era
- Impact of Exposure to ART for Prevention of Mother-to-Child Transmission on the Efficacy of PI-based ART in a Subsequent Pregnancy: The French ANRS EPF Cohort
- TB Screening and Impact in PMTCT
- Maternal TB Is Associated with Increased Risk of HIV Mother-to-Child Transmission
- Provider-Initiated Screening for TB among Pregnant Women in Antenatal Clinics in Soweto, South Africa
- Breast Milk Shedding of HIV and ART Impact
- Breast Milk Exposure to HIV through Compartmentalized Viral Shedding as a Cause of Postnatal Infection
- Effect on Cell-free and Cell-associated Breast Milk Virus of NNRTI-based and PI-based Regimens Administered to HIV-infected Women for the Prevention of Breastfeeding-associated Transmission
- New Insights into Molecular Mechanisms of MTCT
- Elevated Placental Cytokines Levels Are Associated with in Utero HIV-1 MTCT
- Innate Inhibitory Activity of Amniotic Fluid against HIV-1: A Potential Role in Prevention of in Utero Transmission
- IL-10-1082-G/A Promoter Variant Alters HIV-1 Mother-to-Child-Transmission in African Mother-Infant Pairs Exposed to Zidovudine at Delivery
- ART Pharmacokinetics and Safety during Pregnancy and Breastfeeding
- Pharmacokinetics of Lopinavir Boosted with Ritonavir (400/100 mg, Twice Daily) Initiated during the Third Trimester of Pregnancy in HIV-1-infected Thai Women
- Steady State Pharmacokinetic of Ritonavir-boosted Atazanavir in 31 Pregnant Women before and after Delivery
- Boosted Fosamprenavir Pharmacokinetics during Pregnancy
- Tolerance and Viral Resistance after sdNVP and Short-course TDF/FTC)in Delivering Women and Neonates to Prevent MTCT of HIV-1: The TEmAA ANRS 12109 Trial, Step 2
- Impact of Systemic and Mucosal NVP Levels on Serial HIV RNA Levels in Maternal Plasma and Breast Milk after Perinatal sdNVP
- Population Pharmacokinetics of Nevirapine in HIV-1-infected Pregnant Women and Their Neonates: TEmAA ANRS 12109
- Persistence of Resistance and Treatment Outcomes in Women after Single-dose Nevirapine
- Greater Persistence of Drug Resistance Mutations in HIV-1 Subtype C than Other Subtypes among Women Exposed to sdNVP for the PMTCT
- Emergence and Persistence of Nevirapine-resistant HIV in Breast Milk after Single-dose Nevirapine Administration
- Long-term Clinical Outcomes on ART among Women with Prior Exposure to Intrapartum Nevirapine
- Virological Failure Rates among Women Exposed to sdNVP Compared to Women not Exposed to sdNVP: Results from CIPRA-SA
- NVP Resistance Mutations among Women Exposed to a sdNVP Intrapartum More than 1 Year Prior to Starting NNRTI-based ART Are not Associated with Virologic Failure
- HIV Drug Resistance in Breastfeeding Infants Exposed to ART
- Transmission of NVP-resistant HIV-1 to Infants by Breastfeeding Observed after Maternal sdNVP
- Comparison of NVP Resistance among HIV-infected Infants Who Received Extended NVP plus ZDV Prophylaxis vs Extended NVP Prophylaxis Alone: The PEPI-Malawi Study
- Delayed Clearance of High-frequency NVP-resistant Viremia in the First Year of Life in HIV-infected Infants Who Received Extended NVP for Prevention of Breast-milk Transmission: Implications for Early Therapy
- Multi-class Drug Resistance Arises Frequently in HIV-infected Breastfeeding Infants Whose Mothers Initiate HAART Postpartum
- Infant Outcome after Prenatal ART Exposure
- Prenatal Exposure to Antiretrovirals among HIV-exposed but Uninfected Children: Surveillance Monitoring for ART Toxicities Study
- Pregnancy, Efavirenz, and Birth Outcomes in Johannesburg
- Prevalence of Congenital Anomalies in Infants with in Utero Exposure to Antiretrovirals: IMPAACT P1025
- Outcomes in Infants Born to HIV-infected Mothers Receiving Long-term ART in the DART Trial, 2004 to 2009
- Tenofovir Therapy during Pregnancy Does not Affect Renal Function in HIV-exposed Children
- Exposure during Gestation to HAART, Including Tenofovir, Does Not Impair Bone Status and Metabolism in HIV- Children Born to HIV+ Mothers
- Increased Risk of Severe but Reversible Anemia following Perinatal Exposure to Maternal HAART in Infants in Botswana
- Impact of HAART and Short-course Zidovudine on Longitudinal Growth of HIV-exposed Uninfected Breastfed Infants, Botswana
- Mode of Delivery and Neonatal Respiratory Morbidity among HIV-exposed Infants from Latin America and the Caribbean: The NISDI Perinatal Study
- ART Outcomes among Women
- The Effect of Low Sexual-Relationship Power on Viral Load Suppression among Women Receiving ART in Mbarara, Uganda
- A Simple Screening Question about Recent Trauma Predicts HIV-related Health Outcomes and Transmission Risk Behavior among HIV+ Women and Female-identified Transgenders
- Contraception Use and Drug Interactions
- Use of Contraception among HIV-infected Women of Reproductive Age in Northern California
- Effect of the Levonorgestrel Intrauterine Device on Endocervical and Cervico-Vaginal HIV RNA Shedding among HIV-infected Kenyan Women
- Pharmacokinetic Interactions between the Hormonal Emergency Contraception, Levonorgestrel, and Efavirenz
- Improving Estimates of HIV-1 Incidence
- Improved Precision of Cross-Sectional HIV Incidence Testing Using a Multi-assay Algorithm that Includes BED and an Avidity Assay with Modified Assay Cut-offs
- Development of a Bead-based, Multiplex Assay for Estimation of Recent HIV-1 Infection
- Antibody Avidity-based Assay for Identifying Recent HIV-1 Infections Based on Genetic Systems TM ½ plus O EIA
- Concordance of Recent HIV Infection between 3 STARHS Assays Is Not Dependent on Patient Characteristics
- Performance of BED-CEIA and Avidity Index Assays in a Sample of ART-naïve, Female Sex Workers in Kigali, Rwanda
- New HIV-1 RNA Assays and Reagents
- Evaluation of Extraction-Quantification Systems COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, Version 2.0 versus M2000SP/Abbott RealTime® HIV-1 in HIV-1 Group M Subtypes B and Non-B, Group O, and Group P Samples
- Evaluation of the New Roche Cobas Taqman Version 2.0 Quantitative HIV-1 RNA Real-time PCR
- Large-scale Comparison of Roche COBAS Ampliprep/COBAS TaqMan and Abbott RealTime HIV Assays
- Development of a HIV-1 Viral Load Proficiency Test Panel Using Dried Tube Spots
- Beyond B: HIV-1 Viral Load Multi-assay Comparison in a Cohort of Canadian Patients with Diverse HIV Subtype Infections
- New Diagnostic Technologies
- Rapid Extraction and Amplification of HIV-1 DNA from Whole Blood Using a Disposable Microfluidics Device
- Multiplexed Point-of-Care System for HIV and Co-infection Serodiagnosis
- Encouraging Point-of-Care PIMA CD4 Testing Performance in a Laboratory Setting: Johannesburg, South Africa
- Preclinical and Animal Studies of Microbicides/PrEP
- L’644, a Cholesterol Derivatized Version of the gp41 Fusion Peptide C34, Provides Superior Activity in Preclinical Microbicide Assays
- Tenofovir Gel Protects Macaques Against SHIV Exposures Three Days after Vaginal Application
- SHIV-specific T Cell Responses During Successful PrEP and Following Infection During PrEP
- C5A Prevents the Disruption of the Genital Epithelial Barrier by Herpes Simplex Virus
- New Insights on Male Circumcision
- Acceptability of Male Circumcision Among Adolescent Boys and Their Parents/Guardians in Two Villages in Botswana
- A Comparison of Self-reported and Physical Examination Based Male Circumcision Prevalence Rates in Lesotho
- Bayesian Monitoring of the Randomized Trial of Male Circumcision for HIV Prevention in Rakai, Uganda: Statistical Alternatives and Public Health Implications
- Associations Between Male Circumcision and HIV Serostatus in the Multicenter AIDS Cohort (MACS)
- Insights into Post-exposure Prophylaxis
- An Open Randomized Multicenter Clinical Trial Comparing Zidovudine/Lamivudine (ZDV/3TC) Plus Lopinavir/r (LPV/r) or Plus Atazanavir (ATV) Used as Postexposure Prophylaxis (PEP) for HIV Infection
- Use and Sharing of Antiretroviral Medications for Pre- and Post-exposure Prophylaxis to Prevent Sexual Transmission of HIV Among High-risk, Substance-using Men Who Have Sex With Men in Four US Cities
- Characteristics of and HIV Seroconversion Among Patients Receiving Non-Occupational HIV Post-Exposure Prophylaxis in a Sexually Transmitted Disease Clinic - San Francisco, 2007 to 2009
- New HIV Prevention Strategies and Modeling of Impact
- Demographic, Behavioral, and Clinical Characteristics of HIV-1 Serodiscordant Couples Enrolled into an Efficacy Trial of Pre-Exposure Prophylaxis
- HIV Partner Notification is Feasible in Sub-Saharan Africa with a High Yield of Newly Diagnosed HIV Infection
- Declines in Partners Exposed to Risk of HIV Infection: the CDC Prevention in Care Settings (PICS) Study
- Cost-effectiveness of Early Use of Antiretrovirals for Prevention and Treatment of HIV Infection
- The Potential Impact of Recent Infections, HIV Testing and Start of Antiretroviral Drugs at a CD4 of <350 on the HIV Epidemic in a Rural Area in Zambia: a Mathematical Model
- Test and Treat: Forecasting the Clinical and Epidemiological Impact of Expanded HIV Screening and Immediate ART in Sub-Saharan Africa
- Economic Analysis of ART for Prevention of HIV Transmission in a South African Generalized HIV Epidemic Setting
- A “Test and Treat” Strategy In South Africa Is Likely to Lead to a Self-sustaining Epidemic Composed of Only NNRTI-resistant Strains
- Risk Behaviors for HIV Infection
- Determinants of Unprotected Sexual Contacts in HIV-infected Persons: The Swiss HIV Cohort Study
- Concurrent Partnerships, Non-Monogamous Partners, and Substance Use Among Women in the United States
- Bridging the Epidemic: HIV in Clients and Sex Partners of Female Sex Workers in Kampala, Uganda
- Epidemiologic Characteristics Associated with HIV-1 Transmission Linkage among Serodiscordant Couples in an HIV-1 Prevention Clinical Trial
- A Comparison of Sexual Behavior Patterns among Heterosexual Men and Women and Men Who Have Sex with Men
- High HIV Prevalence Despite Lower Rates of Sexual Risk Behaviors Among MSM of Color in Washington, DC
- Risk Behavior and HIV Prevalence among MSM in a Predominantly Muslim and Multi-Ethnic Society: A Venue-Based Study in Kuala Lumpur, Malaysia
- Behavior Change in Year following Diagnosis with Recent HIV-infection among Southern California Men Who Have Sex With Men
- Sexual Behavior of HIV-positive Persons Before and After One Year of Antiretroviral Therapy at the Infectious Diseases Clinic, Kampala, Uganda
- The Intersection between Sex and Drugs: HIV Prevalence Among Sexual Partners of IDU in Chennai, India
- A Randomized Trial Comparing On-Site Treatment with Buprenorphine/Naloxone vs Referral to an Opioid Treatment Program for Opioid-Dependent Patients in an Urban HIV Clinic
- HIV Disease Progression
- Longitudinal CD4 Cell Count Evolution During HIV Natural History: Comparison between European and Sub-Saharan African Seroconverter Cohorts
- Differences in Time to AIDS and Death Following HIV Seroconversion According to Geographical Origin
- Are HIV-Infected Persons Progressing Faster After HIV Diagnosis Over the Epidemic?
- Heterogeneous Immuno-Virological Outcomes in the 81 Patients Enrolled in the ANRS HIV Controllers National Observatory
- Late Presentation for HIV Care in the United States and Canada
- CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS)
- Identifying Persons at Risk for HIV Infection
- Temporal Trends in Attitudes Toward Homosexuality Among African American and White Adults in the General Social Survey, 1973 to 2008
- Phylogenetic Analysis Shows Insularity with Respect to HIV Transmission of Young Black Men in Mississippi Who Have Sex with Men
- Risk Determinants of Men-Who-Have-Sex-With-Men (MSM) Transmission Cascades
- Spatial Clustering of HIV Prevalence in Atlanta, Georgia, and Population Characteristics Associated with Case Concentrations
- Transmission Clusters within Non-B Subtype HIV-1 Infections in the London Area
- Psychological and Smoking Characteristics of Patients at Two Large HIV Clinics: Implications for Smoking Cessation Interventions for HIV+ Smokers
- Characteristics of Foreign-Born Persons Diagnosed with HIV in the US, 2002 to 2007
- Recent Increase in the Incidence of HIV Infection in France
- Identifying HIV Incidence
- Measurement of HIV incidence Among Adults in Kenya and Uganda: A Systematic Comparison of Multiple Methods
- Comparison between Methods to Estimate HIV Incidence Using Serological and Survey Data Collected in Cross-Sectional Studies in St. Petersburg, Russia
- Initial Viral Load after Recent HIV Infection Determined By BED Assay: Michigan
- Effectiveness and Cost-Effectiveness of Universal Acute HIV Screening in the United States
- ART and Transmission
- The Effect of Expanded Antiretroviral Treatment (ART) Strategies on the MSM HIV Epidemic in San Francisco
- Highly Active Antiretroviral Therapy Eliminates HIV Epidemics in a Network Model of an Injecting Drug User Community
- Highly Active Antiretroviral Therapy (HAART) as a Strategy for Reduction of HIV-1 Transmission in Sub-Saharan Africa: Survival and Virus Load Parameters from the Drug Resource Enhancement Against AIDS and Malnutrition (DREAM) Program
- Comparative Effectiveness of HIV Testing and Treatment in Highly Endemic Regions
- Estimating the Rate of HIV Transmission by Men on Treatment
- Estimation of the Proportion of New HIV Cases among Men Who Have Sex With Men (MSM) Transmitted from Persons in Different Stages of HIV Infection, Diagnosis, and Treatment
- Identifying HIV Infection
- Rapid HIV Screening: Missed Opportunities for Diagnosis and Prevention
- HIV Rapid Testing of Previously Untested Sexual Partners of HIV-negative Women Delivering at a Large Public Hospital- a Case Finding Strategy
- Results from a Multimedia Testing and Counseling Program in an Urban Emergency Department
- The Men’s Sexual Health Project (M*SHP): Targeted Screening for Acute and Recent HIV Infection in a Population of Highly Sexually Active Men Who Have Sex with Men (MSM) Attending Commercial Sex Venues, Events, and Parties (CSVEP) in New York City (NYC)
- Opt-Out HIV Testing on Prison Entry Increases the Proportion of Individuals Screened for HIV and the Number Testing Seropositive
- High HIV Risk, Non-IDU Heterosexuals: Can We Find Them Using a Place-Based Methodology?
- Impact of Anticipated and Actual HIV Status of TB Evaluation Patients on Referral and Acceptance of Household Testing in Kampala, Uganda
- Routine HIV Testing of Family Members of Hospitalized Patients in Nigeria: a Novel Approach for Scale-up of HIV Testing Services
- Mental Health, Substance Abuse, and HIV in Resource-limited Countries
- Depression and HIV in Botswana: a Population-based Study on Gender-specific Socioeconomic and Behavioral Correlates
- Depression Symptom Severity Is Associated with Missed Doses, Treatment Interruptions, and Viral Failure among HIV+ ART-treated Individuals in Rural Uganda
- Gendered Effects of Food Insecurity on Depression among HIV-Infected Persons Accessing Antiretroviral Therapy (ART) in Rural Uganda
- Hazardous Alcohol Use and Depression: Impact on Treatment Adherence in Nigeria
- Density of Registered and Unregistered Shebeens and HIV Prevalence in a Migrant Town, Namibia, 2005 to 2009
- HPV and HIV
- Safety and Immunogenicity of the Quadrivalent HPV Vaccine (qHPV) in HIV-Infected Men: Primary Results of AIDS Malignancy Consortium Trial 052
- A Randomized Trial of Male Circumcision and High Risk Human Papillomavirus in HIV-infected and Uninfected Men
- Oral Human Papillomavirus (HPV) Infection Among HIV-infected Men Who Have Sex with Men
- Incidence and Predictors of Abnormal Anal Cytology in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN)
- High-Risk HPV Prevalence by HIV-1 Status in Spanish Men Who Had Sex with Men (MSM) in an Out Patient Sexually Transmitted Diseases Clinic and in a prospective cohort of HIV-positive MSM and women belonging to Spanish Multicenter Cohort (CoRIS)
- Association of HIV Viral Load and CD4 with HPV Infection and Clearance in HIV-infected Women Initiating HAART
- HIV and STD
- High Proportion of New HIV Diagnoses Among Patients Presenting with Syphilis
- High Prevalence of Asymptomatic Sexually Transmitted Infections in HIV-Positive MSM, Visiting HIV Outpatient Clinics in the Netherlands
- A Prospective Study of Vaginal Trichomoniasis and HIV-1 Shedding in Women on ART
- Anal Sex, Sexually Transmitted Infections, and HIV Incidence in Female Sex Workers in Urban Kenya
Posts
Should you honestly desire to be free from the chains of sicknesses, call or write Doctor white now on >: OO2349091844595 and email:- drwhitethehivhealer@gmail.com , I’m Aldrich Rexton from Canada. How indebted I’m to this man called Doctor WHITE for being an instrument to cure me from HIV/AIDS and my youngest sister from HEPATITIS respectively. He was introduced to him by a Brazilian doctor who have also benefited from his herbal viral cure 6years ago. He said to me “Doctor White is gifted, a man of few words and trusted. Call him and you will be glad you did” such words from a highly rated medical doctor prompted me to write him immediately out of curiosity. I told him about my sister and he opted to cure me before my sister this to him was to prove himself. He advised me on things to abstain from during the period of treatment and also go for a laboratory confirmation test after a stipulated time. I took the herbal cure as he prescribed and went for the test right there in the laboratory was my first day to have tears of joy and instantly i requested to purchase hepatitis cure for my kid sister which we tracked online and received in few days for this she takes me as her Idol after she’s cured, our joy is restored. I urged you to keep these contacts as life saving once being it herpes, Cancer, Depression or Diabetes. Save a life today and this will always bring you joy.
ReplyDeleteThanks, Aldrich Rexton
Truly nature can heal it all. I can conveniently say this because I have walked down that road, I have been between the devil and the deep blue sea, I have seen the bad and the ugly in trying to get my life fixed not withstanding how many times I failed i was still determined to get healing because I was young and had dependants. Physicians told me to learn to leave with itching, pains and burnings and continue to take my pills even when they make me depressed. I decided to exploit more by stuffing the internet and researches behold i read a great testimonies of Dr. White {DRWHITETHEHIVHEALER@GMAIL.COM} Published by a sincere survival on national daily. Being a herbalist with a big heart the man I will always call dad and savior, we discussed and he vowed to saved me provided I tell others about him after which he sent me the cure through courier to be used twice daily for 2weeks. My only difficulty was one of the medicines was pretty bitter but Don’t just give up hopes now, keep faith, this man is anointed by the most high to help end your HERPES, other VIRUSES and BACTERIAL infections. Email him today or Watsapp +2349091844595 and thank heaven thereafter. Go through the tunnel it promises to give light at the end. For further guidance write me on {phynmarcel15@gmail.com}
DeleteTruly nature can heal it all. I can conveniently say this because I have walked down that road, I have been between the devil and the deep blue sea, I have seen the bad and the ugly in trying to get my life fixed not withstanding how many times I failed i was still determined to get healing because I was young and had dependants. Physicians told me to learn to leave with itching, pains and burnings and continue to take my pills even when they make me depressed. I decided to exploit more by stuffing the internet and researches behold i read a great testimonies of Dr. White {DRWHITETHEHIVHEALER@GMAIL.COM} Published by a sincere survival on national daily. Being a herbalist with a big heart the man I will always call dad and savior, we discussed and he vowed to saved me provided I tell others about him after which he sent me the cure through courier to be used twice daily for 2weeks. My only difficulty was one of the medicines was pretty bitter but Don’t just give up hopes now, keep faith, this man is anointed by the most high to help end your HERPES, other VIRUSES and BACTERIAL infections. Email him today or Watsapp +2349091844595 and thank heaven thereafter. Go through the tunnel it promises to give light at the end. For further guidance write me on {phynmarcel15@gmail.com}
Delete